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"I meant," said Ipslore bitterly, "what is there in this world that 
makes living worthwhile?" Death thought about it. "CATS," he said 
eventually, "CATS ARE NICE." 
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Short summary 
In vitro cell culture models are an important alternative for animal testing, as they are less 
ethically questionable and avoid the problem of non-representative results due to species 
differences. A previously established 3D co-culture model of the inflamed intestinal 
mucosa consisting of human epithelial and primary immune cells was further developed 
by replacing primary cells by two human monocytic cell lines in order to have a stable and 
more reproducible system, which shows a well preserved ultrastructure and good barrier 
properties. 
With this model the safety of different nanoparticles (NPs) was investigated and it was 
shown that Ag NPs show a high cytotoxicity. Co-culture models incubated with Au NPs 
showed an inflammatory response although no toxic effects were measurable. 
Furthermore, differences between inflamed and non-inflamed co-cultures and Caco-2 
monocultures were shown with the result that Caco-2 cells are more sensitive to toxic 
Ag NPs than the co-culture models. 
For the treatment of inflammatory bowel disease (IBD) nano- and microparticulate drug 
delivery systems (DDS) were developed, containing anti-inflammatory compounds 
budesonide and cyclosporine A. The anti-inflammatory effect of the formulations on the 
inflamed co-culture was shown by TEER and IL-8 measurement.  
In summary, the further developed co-culture model is a useful tool for safety testing of 
nanomaterials and can be used to test anti-inflammatory effects of DDS for the treatment 
of IBD. 
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Kurzzusammenfassung 
In vitro Modelle sind eine wichtige Alternative zu Tierversuchen, da sie ethisch weniger 
fragwürdig sind und nicht-repräsentative Ergebnisse aufgrund von Spezies-Unterschieden 
vermeiden. Ein 3D Co-Kultur Modell der entzündeten Darmmukosa, bestehend aus 
menschlichen Epithel- und primären Immunzellen wurde entworfen, welches in der 
vorliegenden Arbeit weiterentwickelt wurde, indem die Primärzellen durch Zelllinien 
ersetzt wurden, um ein reproduzierbareres Modell zu erhalten.  
Mit diesem Modell wurde die Sicherheit verschiedener Nanomaterialen untersucht und es 
wurde gezeigt, dass Ag NP zytotoxisch wirken. Zell-Modelle, inkubiert mit Au NP, zeigten 
eine entzündliche Antwort, obwohl keine Toxizität gemessen werden konnte. Zusätzlich 
wurde gezeigt, dass Caco-2 Monokulturen empfindlicher gegenüber toxischen Ag NP sind 
als die Co-Kultur Modelle.  
Für die Behandlung entzündlicher Darmerkrankungen wurden nano- und mikropartikuläre 
Arzneistoffträgersysteme entwickelt, die die anti-entzündlichen Verbindungen Budesonide 
und Ciclosporin A enthalten. Der anti-entzündliche Effekt dieser Partikel wurde im 
entzündeten Co-Kultur Modell des Darms durch TEER und Zytokin Messungen gezeigt.  
Dies zeigt: Das weiterentwickelte Co-Kultur Modell ist ein nützliches Werkzeug für 
Sicherheitstests von Nanomaterialien. Darüber hinaus kann es genutzt werden, um anti-
entzündliche Effekte von Arzneistoffträgersystemen für die Behandlung entzündlicher 
Darmerkrankungen zu testen. 
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1 Introduction 
1.1 Intestinal mucosa and inflammatory bowel disease 
Approximately 1014 microorganisms from 1000 different species, corresponding to 10-fold 
the number of cells in the human body, are located in the human gastrointestinal (GI) 
tract. At birth the human intestine is a sterile area and bacterial colonization only begins 
during the delivery process [1]. The intestinal epithelium with its huge surface area 
(~ 100m2) forms a physiological barrier [2], and probiotic bacteria in the GI tract contribute 
to this barrier function through e.g. effects on epithelial tight junction proteins, prevention 
of epithelial apoptosis, increased production of intestinal mucus or increased stimulation 
of defensin production [1].  
Nowadays, inflammatory bowel diseases (IBD) such as Crohn´s disease (CD) and 
ulcerative colitis (UC) are serious and incurable diseases. In the US, about 1-2 million 
people are affected by such diseases [3]. Patients in particular with CD often need 
surgical intervention, and their mortality rate is greater than that of the general population. 
However, the prognosis of IBD patients in general is not so easy to determine [4], and in 
fact, differentiation between diseases may also prove difficult. Both CD and UC affect 
parts of the GI tract and the colonic mucosa. They both show similar symptoms (such as 
diarrhea, fever, muscle aches, abdominal pain, weight loss or bloody stool) and lead to an 
increased risk of colon cancer [5]. However, while CD can cause inflammation anywhere 
in the lining of the GI tract, UC is characterized by a long-lasting inflammation specifically 
in the large intestine [6] (Figure 1.1). So far the detailed pathogenic mechanisms of IBD 
remain to be fully elucidated, although worldwide a strong correlation between IBD and 
environmental factors has been detected [7]. Furthermore, genetics, immune dysfunction 
and changes in the microbiome could be reasons for the appearance of IBD [8]. 
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Figure 1.1: Disease areas and symptoms of CD and UC (based on Lautenschläger et 
al. [9]). 
 
The state of IBD highlights the important role of the microbiome in gut barrier function - in 
IBD patients an excessive, cell-mediated inflammation is induced in response to normal 
bacterial microflora antigens; as a result, an abnormal permeability and gut barrier 
function can be observed in affected and non-affected GI areas [10].  
In the light of the abnormal response to normal gut contents seen in IBD, diet control is 
quite important for IBD patients as a means to control their disease symptoms. The 
removal of specific foods, suspected to worsen patients conditions, is an important factor 
for dietary optimization [11]. The importance of diet is highlighted by the fact that IBD 
occur more frequently in western countries, where diet control is a problem, than in 
underdeveloped regions. Western food, with large amounts of animal fat and proteins and 
comparatively less fiber, may influence the gut microbiome and could increase the risk of 
IBD [12]. However, the other possibility is that people in more industrialized countries are 
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exposed to fewer microorganisms because of the higher hygienic standards in such 
areas, and as a result the immune system is not able to tolerate too many 
microorganisms. Smoking also influences the development of IBD. It was shown that 
smoking increases the risk of extra-intestinal manifestations in CD [13], [14]. Surprisingly, 
smoking seems to protect people from UC, which is largely a disease of non-smokers 
[15]. However, so far the reason for this unusual association remains unclear [16], and 
scientific studies have failed to confirm a beneficial effect of smoking for UC patients [17].  
With respect to the treatment of IBD, several changes in the GI tract must be considered. 
Firstly, the transit time through the intestine varies between healthy and diseased 
persons. In healthy persons the transit time through the small intestine is approximately 
4 hours, and varies in the colon between 6 and 70 hours [18]. Contrary to this, the transit 
time in IBD patients is twice as fast as in healthy persons due to the occurrence of 
diarrhea, which, as mentioned, is a common symptom of this disease [19]; this 
significantly faster transit time makes it very difficult to target drug formulations for IBD 
treatment to the affected regions of the GI tract. Another difference is the colonic pH 
value: in UC and CD patients this is significantly lower than in healthy persons. The 
intestinal pH is influenced by microbial fermentation, intestinal volume and transit times 
[20] – all these are factors which are disrupted during IBD. Furthermore, the mucosal 
integrity is altered by the IBD-associated inflammation as is the mucosal metabolism [21]. 
Additionally, mucus production is higher in diseased tissue [22], which also makes it 
difficult for drug treatment formulations to reach the inflamed area. Therefore, the 
evaluation of new strategies in the treatment of IBD is a point of extreme importance.  
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1.2 Treatment of IBD 
So far there is no medical cure for IBD, and a lifetime of drug therapy for the maintenance 
of life quality is often necessary. A group of anti-inflammatory drugs including 
5-aminosalicylic acid (5-ASA) is commonly used for the therapy of mild types of IBD [23]. 
When this therapy fails patients are often treated with other drugs such as infliximab, 
which is a chimeric monoclonal antibody directed against the inflammation-related 
cytokine tumor necrosis factor-α (TNF-α). Such antibodies increase the production of anti-
inflammatory cytokines including interleukin-4 (IL-4), IL-5 and IL-10, which in turn inhibit 
production of pro-inflammatory cytokines. Corticosteroids are also used as more effective 
drugs in severe forms of IBD. Biological drugs (such as antibodies), 5-ASA and 
immunosuppressants can each be effective in their own way. However, under some 
circumstances medication fails and patients require surgery. In many cases this may 
consist of a colectomy, in which parts of or the entire large intestine is removed. After 
removal cases of UC may be cured, however, CD can still recur after this type of 
surgery [6].  
With respect to medical treatments serious side effects can occur. Many drugs can induce 
side effects ranging from mild to severe in nature; this may even include mortality in some 
cases. Corticosteroids often induce hypertension, osteoporosis and glaucoma as well as 
many other effects. Treatment with immunosuppressants leads to an increased 
susceptibility to infections and malignoma. Therefore it is important to attempt to achieve 
and to maintain a balance between effective IBD treatment and the risk of occurrence of 
adverse drug reactions. The ability to treat IBD with anti-inflammatory agents at an 
effective dose, which does not induce any side effects, would be the ideal situation [9].  
Oral treatment of IBD with anti-inflammatory drugs or antibodies has shown success 
against inflammation [24]. The limitation of such treatments however is that drugs are 
transported non-specifically to cells of the human body, which can also lead to several 
side effects such as headache, vomiting or diarrhea, all of which have the potential to 
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worsen patient conditions [6]. Therefore it is important not only to be able to deliver drugs 
at an effective and safe dose, but also to develop drug delivery systems (DDS) for the 
transport of drugs to the specific target site. For this purpose nano- and microparticulate 
DDS are often used. These can accumulate in the inflamed tissue and release the drug 
specifically at the target site, as shown in Figure 1.2. As mentioned previously the GI tract 
in IBD patients shows disrupted barrier properties and increased mucus production, which 
makes it easier for the particles to accumulate in such affected areas. Furthermore, 
immune competent cells such as macrophages and dendritic cells are able to penetrate 
and migrate through the disrupted barrier, and take up the particles. 
 
 
Figure 1.2: Mechanism of particle accumulation in the inflamed intestinal mucosa. 
Particles may accumulate between epithelial cells, because tight junctions are disrupted, 
or be taken up by macrophages (based on Collnot et al. [25]). 
 
The use of nano- and microparticles is therefore an excellent strategy in the treatment of 
IBD, as an improvement of drug efficacy and colonic uptake can be seen to result from 
inflammation site-specific targeting. A better bioavailability in the diseased tissue and a 
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reduction of side effects resulting from non-specific delivery are also seen. Additionally, 
lower drug concentrations are needed in particulate systems as compared to conventional 
formulations, also reducing the risk of adverse drug effects [25].  
Before such DDS can be used for human IBD patients, it is important to test their efficacy 
and of course their safety in biological models. There are several animal models that can 
be used for investigations related to IBD. 
 
1.3 In vivo models for IBD 
The term “IBD animal model” is defined as a model which is characterized by chronic or 
relapsing inflammation of the GI tract with features resembling human IBD [26]. Two 
models are very often used for this purpose, because of their high reproducibility: the DSS 
model and the TNBS model. In the first case, dextran sodium sulfate (DSS) is given to 
mice orally in their drinking water for five days. Afterwards mice show typical symptoms of 
IBD such as weight loss, diarrhea or bloody stool. Inflammation can be analyzed e.g. by 
histological methods or measurement of inflammatory markers including IL-8 and TNF-α 
[27]. The DSS model is mostly used for investigations of UC, while the TNBS model is 
more often used for CD. In the case of the TNBS model, rodents are treated intra-rectally 
with 2,4,6-trinitrobenzene sulfonic acid (TNBS), which is dissolved in alcohol to induce gut 
inflammation and barrier disruption [28]. While DSS and TNBS are able to readily induce 
symptoms of IBD in model species, many animals die during the experimental time, which 
makes these chemically-induced models in fact rather variable and unpredictable. As an 
alternative, genetically-modified IL-10 knockout mice have been established. In this model 
animals develop a time-dependent IBD-like disorder in the colon [29]. Unfortunately this 
model is more expensive and shows a higher sensitivity than the chemically induced 
models. 
It can therefore be seen that serious problems and difficulties exist with respect to IBD in 
in vivo experiments. Additionally the interpretation of data from animal testing is often 
 Chapter 1: Introduction 
 
12 
 
further complicated by the species differences between rodents and humans. In vivo 
testing in animals in general is also more expensive and ethically questionable in 
comparison to in vitro studies. Furthermore, the new REACH (Registration, Evaluation, 
Authorization and Restriction of Chemical substances) regulations, which also cover 
nanomaterials, greatly increase the number of substances which must be tested thus 
overwhelming the capacities of in vivo animal testing.  
 
1.4 Epithelial in vitro models 
Cell culture-based in vitro models are a very important alternative to animal testing. They 
are often used for studying the processes of drug absorption, distribution, metabolism and 
excretion (ADME). The epithelial cell line Caco-2, a human colon adenocarcinoma cell 
line, which, having been used for the last 20 years as a means to mimic the GI epithelium, 
is an established cell culture model of the human intestinal barrier [30]. A study that 
compared 20 different intestinal cell lines found that Caco-2 cells show the highest 
correlation to the in vivo situation [31]. On permeable cell culture supports Caco-2 cells 
grow in a monolayer and show a cylindrical polarized morphology with microvilli on the 
apical side. They express small intestinal enzymes, transport proteins and functional tight 
junctions [32]. In such a system, the permeable supports on which cells are grown 
generally consist of 10 µm thick polyester or polycarbonate membranes, which are 
incorporated into culture plate insert systems. Such insert systems result in division of the 
cell culture plate well into an apical compartment, which mimics the intestinal lumen, and 
a basolateral compartment, which represents the blood side. To investigate the tightness 
of the Caco-2 monolayer representing the epithelial barrier, the transepithelial electrical 
resistance (TEER) can be measured in these systems, giving readings with the units of 
Ω*cm2. The tighter the epithelium, the higher is the measured TEER value.  
Epithelial cells constitute the major cell type in the intestinal mucosa and cover the 
majority of the intestinal surface (~ 250 m2). Thus they are the main interface for 
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interaction and absorption, and as such the Caco-2 monolayer system has consequently 
been accepted by regulatory authorities as an in vitro model to predict oral drug 
bioavailability. The Caco-2 in vitro model is a very useful means to investigate the 
absorption and permeation of small drug molecules because Caco-2 cells grow into 
monolayers with a differentiated phenotype with many functions of the small intestinal 
villus epithelium [33].  
However, one cell type alone cannot mimic the behavior of a whole tissue. Therefore, 
while Caco-2 monolayers are a very important tool for drug absorption and bioavailability 
studies, there are some limitations to this model with respect to its use in other 
applications. An important limiting factor in the case of safety testing for example is the 
lack of immune competent cells (e.g. macrophages and dendritic cells), which play a key 
role in the response to exposure to toxic materials (such as certain nanoparticles). 
Furthermore, the presence of immune cells is very important for studies concerning 
inflammation, as they are responsible for the production of pro-inflammatory cytokines 
such as IL-8, IL-6 or TNF-α. Therefore, the development of novel co-culture systems, 
consisting of two or more cell types, is very important for in vitro testing of nanomaterials 
or drug delivery systems. 
 
1.5 In vitro co-culture models of the intestine 
Several co-culture models have already been established and are well described in 
literature. A lot of these models are related to the lungs and respiratory tract, as for 
example the model from Rothen-Rutishauser et al., which consists of epithelial cells 
(A549), macrophages and dendritic cells, and is designed to study the interaction of lung 
tissue with nanoparticles (NPs) [34]. This model was even further developed by using 
primary alveolar type I cells to present a more realistic alveolar barrier [35].  
Regarding intestinal co-cultures, several models have been established in order to 
investigate the penetration of drugs or NPs, many of which include M-cells and goblet 
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cells. M-cells play a role in the uptake and delivery of NPs or other substances, whereas 
goblet cells produce mucus (in far greater quantities than Caco-2 cells alone), which also 
influences the permeability of the epithelial layer. In a typical example of such a co-culture 
des Rieux et al. developed a model of Caco-2 cells with M-cells. In order to produce such 
a model Caco-2 cells were seeded in the apical compartment of a transwell filter insert 
and Raji B cells were introduced into the basolateral compartment [36]. These cells 
release soluble mediators which are responsible for differentiation of Caco-2 to M-cells. 
Des Rieux et al. further improved this model by inverting the insert with the Caco-2 cells to 
get closer contact between the two cell types, making such a model physiologically more 
relevant for permeability studies with NPs because it leads to more efficient cell 
differentiation [37].  
A similar model was established by Antunes and colleagues, who combined Caco-2 and 
Raji B cells with the mucus-producing cell line HT29. They developed one model with 
Caco-2 and HT29 cells seeded in the apical and Raji B cells in the basolateral 
compartment and one model in which the converse was true. With both models they 
performed permeability studies which showed that such a triple culture model leads to 
more reliable results than in vitro models with one or even two cell types because it could 
be seen that insulin permeation was faster in the triple culture models [38].  
Araújo et al. established a similar model with Caco-2, HT29-MTX and Raji B cells with a 
seeding ratio of 90:10 between Caco-2 and HT29-MTX cells in order to closely mimic the 
physiological proportion of each cell [39]. Yet further studies have shown that the seeding 
day is important for such co-culture systems: when Caco-2 cells were grown for 21 days 
and HT29-MTX cells were seeded after different time points, it was found that after earlier 
seeding more goblet cells were present, which influenced the permeability of luciferase 
yellow and rhodamine123 [40]. The latest co-culture system with Caco-2, HT29-MTX and 
Raji B cells was established in 2014 by Schimpel et al., who also performed permeability 
studies with drugs and NPs and could show that goblet and M-cells have a huge influence 
in these studies [41]. 
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As already mentioned all these models were developed for the purpose of permeability 
testing: there are even more co-culture models of the intestine in existence for other 
purposes. A model with Caco-2 cells in the apical compartment and lymphoblastoid TK6 
cells in the basolateral compartment of transwell inserts was established for modelling the 
role of intestinal first-pass effects (such as absorption and metabolism) in the genotoxicity 
of orally-delivered drugs [42]. Other models with human submucosa and HT29-CI.16E as 
epithelial cells have been used to investigate the role of the human enteric nervous 
system in the control of the intestinal lumen organization and proliferation [43], while 
models with Caco-2 cells and peripheral blood mononuclear cells (PBMCs) in different 
compartments of a transwell system have been employed to determine reactivity to non-
toxic bacterial signals [44]. Holland-Gunz et al. seeded enteric glial and nerve cells from 
rats in a collagen layer with HT29 enterocytes on top to prepare a basic model suitable for 
placement on cover slips [45].  
Yet further models have been established for cytotoxicity testing, such as one model with 
Caco-2 cells in the apical compartment and PBMCs in the basolateral compartment of a 
transwell system. Toxicity studies performed with arsenic showed that the release of the 
pro-inflammatory marker TNF-α was increased, more in the basolateral compartment with 
PBMCs than in the apical compartment with the Caco-2 cells which proves how important 
immune competent cells are for pro-inflammatory reactions. This model was also inflamed 
with bacteria-derived lipopolysaccharides (LPS), which showed an even further increase 
in the amount of produced TNF-α [46].  
As has been discussed, the ability to mimic a state of inflammation is a very important 
factor for IBD models. There are some fundamental differences between healthy and 
inflamed tissue as for example epithelial barrier disruption. Bisping et al. established a co-
culture model with epithelial cells (Caco-2 or primary cells) together with PBMCs from 
healthy persons, or from IBD patients. The models containing cells from IBD patients 
released significantly more Interferon-γ (IFN-γ), a pro-inflammatory marker, than the 
models containing cells from healthy persons [47]. In addition to IFN-γ, other pro-
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inflammatory cytokines can also be up-regulated in a state of inflammation leading to 
several measurable inflammatory markers. As the epithelial barrier is disrupted in 
inflammatory states, TEER values of the epithelial barrier can also be monitored. A 
decreasing TEER value can be used as an indicator of inflammation, as was observed in 
the co-culture model of Tanoue et al. after inflammation with LPS [43]. Other co-culture 
models available for IBD include a model with T84 epithelial cells, CCD186 myofibroblasts 
and lamina propria mononuclear cells, designed for the investigation of the interaction 
between cell types and evaluation of their role in barrier integrity [48], and a model with 
Caco-2 and THP-1 cells, which showed a disrupted epithelial barrier, low TEER values 
and high TNF-α release from activated THP-1 cells [49]. 
However, despite the existence of these numerous models, so far only one model has 
demonstrated good barrier properties suitable for NP translocation studies. This model 
combines the Caco-2 intestinal epithelial cell line with primary blood-derived dendritic cells 
and macrophages embedded in a collagen type I gel [50] and was developed in our 
research group. In this setup also a reversible inflammation could be induced by addition 
of the pro-inflammatory cytokine IL-1β, and the model was successfully applied to the 
testing of anti-inflammatory formulations, such as NPs, for the treatment of IBD [51]. Due 
to the presence of immune cells, this model should also be a useful tool to test cytotoxicity 
of NPs, which is a very important point, because NPs are frequently used in food 
packages, sun creams and wound healing products. 
 
1.6 Nanoparticles 
NPs by definition have a size between 1 and 100 nanometers, and differ from other 
materials as a result of their large relative surface area. Because of this huge surface area 
they can show differences in properties such as reactivity, strength and electrical 
characteristics relative to other materials [53]. Furthermore, interaction of NPs with 
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biological media and cells is different to that of micro- and macrostructured materials as 
absorption pathways and cellular internalization differ.  
Currently, nanoparticles can be found in many consumer products. They serve for 
example as surface coatings in paints, in food packages or in sun cream. Research on 
NP-associated toxicity has been focused for a long time on airborne particles. However, a 
large fraction of these particles never reaches the deeper lung, as particles impact in the 
throat and upper airways and are removed from the bronchi by mucociliary clearance, to 
be swallowed afterwards. Thus, such NPs in fact gain access to the GI tract. More 
importantly, engineered nanomaterials are also employed in food packaging or as 
additives in various food products. As already mentioned, they are also used in innovative 
drug delivery systems as they can passively or actively target drugs to their site of action 
and can protect their cargo from degradation [52].  
There is still a huge concern about the safety of nanomaterials. Engineered nanomaterials 
can often be found in textiles and can end up in soils or wastewater [54]. Other 
nanomaterials are also used in construction and related infrastructure industries [55] and 
many NPs are used as food supply through novel applications, nutrient and bioactive 
absorption, improved colors and flavors or food packaging [56]. All these points make it 
very important to know more about the possible toxicity of nanomaterials, especially after 
reaching the GI tract. 
 
1.7 Aim  
The first step of this work was to further develop the co-culture model of the inflamed 
intestinal mucosa, as established by Leonard et al. [50], by replacing the utilized primary 
immune cells with cell lines. Primary cells show a high variability, as they are isolated from 
different patients` blood samples. Additionally the isolation of the cells for every 
experiment is time consuming and expensive. The use of cell lines in such a model would 
therefore make the model more reproducible and easier to use. For this purpose THP-1 
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cells were stimulated with phorbol-12-myristate-13-acetate (PMA) in order to facilitate 
differentiation to macrophage-like cells; MUTZ-3 cells were used as dendritic-like cells and 
both were co-cultivated in a collagen layer with Caco-2 cells on top in order to mimic the 
intestinal mucosa (Figure 1.3).  
 
 
 
Figure 1.3: Experimental setup of the co-culture of the inflamed intestinal mucosa. 
Dendritic cells and macrophages are embedded in the collagen layer. Epithelial cells are 
seeded on top of the collagen. The model can be inflamed by adding of IL-1ß into the 
apical compartment. 
 
Following replacement of the primary cells by cell lines, it was tested whether the model 
showed the same behavior as previously, in order to see if the replacement of the cells 
was successful. Therefore, IL-1ß was used as an inflammatory stimulus. Barrier 
properties (TEER) and release of the pro-inflammatory cytokine IL-8 were monitored and 
compared between the previously developed, primary cell containing model and the newly 
developed, cell line-based model.  
As a second task the newly-established co-culture model was used to test the cytotoxicity 
of different engineered NPs. Ag, TiO2 and two differently-sized Au NPs were tested in 
different concentrations with 24 hours incubation times. These particles are often used in 
food packages, tooth paste or in the medical field; they therefore have a high degree of 
exposure, which makes it very important to test the safety of these particular engineered 
nanomaterials. Cytotoxicity was measured by cell membrane damage (LDH assay), 
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mitochondrial activity (Alamar Blue assay), membrane integrity (TEER) and inflammation 
(IL-8 and TNF-α release). The results of inflamed and non-inflamed co-culture were 
compared to the results with a non-inflamed Caco-2 monoculture, to observe if they react 
differently due to the presence of immune cells and to determine whether the co-culture 
model showed a more realistic result than a model containing just one cell type. 
The last part of this thesis shows another investigated application of the further developed 
in vitro system: the efficacy of drug loaded nano- and microparticles was tested within this 
model, in the context of local anti-inflammatory drug therapy. Budesonide- and 
cyclosporine A- (two anti-inflammatory drugs) loaded nano- and microparticles prepared 
by spray-drying and nanoprecipitation (PhD thesis, Christina Draheim) were used to treat 
the inflamed co-culture. The anti-inflammatory effect was determined by TEER and IL-8 
measurements. Results were compared to culture treatment with free drug solution and 
blank nano- and microparticles. Confocal images showed the accumulation behavior of 
the particles in the cell culture model. 
Therefore, the overall aim of this thesis was to show the successful further establishment 
of the co-culture model of the inflamed intestinal mucosa, constituted of cell lines, to use it 
as a tool to test not only the cytotoxicity of nanomaterials, but also the efficacy of 
nanomedicines. 
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2 Replacement of primary cells by cell lines in a 3D co-culture 
model of the inflamed intestinal mucosa 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter have been published in: 
J. Susewind, C. de Souza Carvalho-Wodarz, U. Repnik, E.-M. Collnot, 
N. Schneider-Daum, G. W. Griffiths, and C.-M. Lehr, “A 3D co-culture of 
three human cell lines to model the inflamed intestinal mucosa for safety 
testing of nanomaterials,” Nanotoxicology, vol. 5390, pp. 1–10, 2015.  
Julia Susewind made the following contributions to this publication: 
performed all cell culture experiments, measured TEER and IL-8 data, 
made confocal images, analyzed all data and wrote the manuscript. 
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2.1 Introduction 
In vitro cell culture models are very important tools for safety testing, permeability studies 
and efficacy studies of newly developed drugs. There are a lot of established in vitro 
models for many purposes. For the intestine the most frequently used and well-
established model is the Caco-2 cell model, which is commercially available. As already 
mentioned in the first chapter, this is a human colon adenocarcinoma cell line, which has 
been used for the last 20 years as model for the intestinal barrier [30]. The most frequently 
used Caco-2 clone is clone C2BBe1. The clone HTB37 is the parental Caco-2 clone, from 
which the cell line Caco-2 C2BBe1 was cloned in 1988 by limiting dilution. Caco-2 cells 
exhibit structural and functional differentiation patterns typical of enterocytes: the surface 
of the cell layer is covered by brush border microvilli, tight junctions are formed between 
the cells and a polarization of the cell monolayer can be seen [57]. The brush border of 
these cells is comparable to the human colon and contains microvillar proteins such as 
villin, fimbrin and sucrose-isomaltase [58]. In a comparison of different colon carcinoma 
cell lines, it was found that Caco-2 cells exhibit a better morphological and functional 
differentiation to enterocyte cells than the other tested cell lines [31]. Caco-2 cells can be 
grown on permeable filter supports in cell culture plates that form an apical and a 
basolateral compartment to better mimic the in vivo conditions of the intestinal lumen and 
blood side respectively. These supports also allow the free access of ions and nutrition to 
both sides of the epithelial monolayer, which leads to an even further improvement in 
morphological and functional differentiation. Furthermore, this enables the model to be 
used in transport and toxicity studies. The integrity of the cell monolayer can be measured 
via TEER with an EVOM (epithelial voltohmmeter) and ultrastructural morphological 
analysis can be performed via electron microscopy [30].  
A limitation of the Caco-2 cell model is that it is not a good tool for absorption or toxicity 
studies of small molecules or entities, such as nanoparticles. Furthermore, in vivo 
interactions of molecules with the intestinal mucosa are not limited to enterocytes. For this 
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reason, it is also important to look at other cell types. Specialized epithelial cells, the so-
called M-cells, and antigen presenting cells have shown a great ability to internalize nano- 
and microparticles. Many NPs are first taken up by phagocytes of the immune system 
(e.g. macrophages). These interactions between immune system and nanomaterials can 
lead to inflammatory reactions. Immune cells recognize NPs by their surface properties 
and mount an inflammatory response which includes the release of cytokines [59]. 
Although the immune system`s task is to protect the body from foreign substances, the 
immune response against the NPs can lead to toxicity [60]. Thus monocultures of 
epithelial cell lines are not sufficient to mimic this complex interplay of cells and particles. 
The predictive power of in vitro models could be enhanced in a co-culture setting of innate 
immune cells and epithelial cells.  
Another point that has to be considered for in vitro models of IBD is the inflammation 
status. In IBD patients several regions of the human intestine show inflamed areas. This 
should also be addressed in an appropriate in vitro model. Caco-2 cells alone cannot 
mimic this inflammation because other cell types, such as immune cells, play key roles in 
this process. Therefore, a 3D co-culture of the inflamed intestinal mucosa was developed 
by Leonard et al. [50] with Caco-2 cells together with primary blood mononuclear cells 
(PBMCs), which were isolated from blood samples and differentiated to macrophages and 
dendritic cells. The immune cells were seeded in a collagen layer with Caco-2 cells as 
epithelial barrier on top. It could be shown that this model exhibits good barrier properties 
after a growth time of 21 days. After inflammation with IL-1ß a decrease of TEER and an 
increase in production of IL-8, a pro-inflammatory cytokine, could be measured. 
Furthermore, the inflammation was reversible - it could be shown that after removal of 
IL-1ß a decrease of IL-8 release and increase of TEER back to the starting value before 
inflammation occurred [50]. However, there are some limitations of this model related to 
the use of primary cells. These cells have to be isolated from buffy coats, which is an 
expensive and time-consuming procedure. An even more important point is that the blood 
comes from different patients with different conditions of the cells, which is a problem for 
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the reproducibility of the model. Cell lines offer an advantage over primary cells in this 
respect, as they are a homogeneous population. Therefore our aim was to replace the 
primary cells in the previously developed triple culture model with cell lines. Two human 
monocytic cell lines were chosen for this purpose: THP-1 and MUTZ-3. 
MUTZ-3 is a CD34+ human myeloid leukemia-derived cell line that is commercially 
available. A comparison with other human cell lines such as KG1 (myeloblasts from bone 
marrow) and THP-1 (monocytes from blood), which are also able to form a dendritic cell-
like phenotype after stimulation, showed that this cell line shows the best DC-like 
phenotype [61] [62]. Other human (HL-60) or mouse (D1, J774, Raw264.7) cell lines are 
also able to acquire a dendritic cell-like phenotype [63], but their functional and 
transcriptional profiles are not known or not very similar to primary dendritic cells. For 
MUTZ-3 cells it was successfully shown that they can activate T-cells, which is attributable 
to the expression of co-stimulatory molecules as CD80 and CD86. Therefore, this cell line 
is a suitable model for deciphering the molecular mechanism of immune reactions [62].  
The THP-1 cell line, which is also commercially available, is a human monocytic leukemia-
derived cell line, which can be differentiated to macrophage-like cells after stimulation with 
phorbol-12-myristate-13-acetate. These cells mimic monocyte-derived macrophages and 
since their establishment 30 years ago they have become one of the most often used cell 
lines to replace primary macrophages in in vitro models [64]. THP-1 cells are suspension 
cells which adhere to the bottom of the cell culture flask after stimulation with PMA. During 
this process PMA induces a cell cycle arrest in the G1 phase via complex mechanisms 
and an upregulation of several proteins [65]. Furthermore, the cell volume increases, the 
nucleus becomes more irregular in shape and many phagocytic vacuoles appear in the 
cell cytoplasm [66]. It has also been shown that THP-1 cells exhibit surface markers 
typical of macrophages after stimulation with PMA, such as CD14 and TLR2 [67]. 
By replacing the primary cells in the intestinal in vitro model with the above cell lines, it is 
expected that the model should be more robust and lead to more reproducible results. 
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The aim of the work presented in the current chapter was therefore to show that both 
models (the previous model using primary immune cells and the model to be developed in 
which only cell lines are employed) show the same behavior after inflammation. In order to 
investigate this, the models were grown until Caco-2 cells formed a confluent monolayer. 
Afterwards IL-1ß was added to the apical compartment to inflame the models. TEER was 
measured to see if the inflammation was accompanied by opening of tight junctions, which 
would lead to a decrease of TEER values. It was also important to see if the inflammatory 
effect was reversible after removal of IL-1ß, as was observed in earlier studies with the 
primary cell-based model. Furthermore, IL-8 release was measured after inflammation 
and after removal of IL-1ß. The ultrastructure of the model was observed via transmission 
electron microscopy (TEM) and confocal laser scanning microscopy (CLSM) to see if both 
immune cell types continued to be viable after three weeks in the collagen layer and if the 
cells were able to move within and out of the collagen, as was shown for the previous 
model. 
Since the Caco-2 clone C2BBe1 needs 21 days to form a confluent monolayer, it was also 
tried to use the Caco-2 clone HTB37, which grows faster and shows higher TEER values 
after a shorter time. As this could lead to a higher experimental throughput, the second 
aim of the following work was to replace clone C2BBe1 by clone HTB37 without changing 
the inflammation behavior of the model [50].  
 
2.2  Materials and Methods 
2.2.1 Cell culture 
Caco-2: clone C2BBe1 (passages 60-80) and clone HTB37 (passages 25-45) of the 
adenocarcinoma cell line were both obtained from the American Type Culture Collection 
(ATCC) (Rockville, MD). Clone C2BBe1 was grown in Dulbecco`s Modified Eagle Medium 
(DMEM) (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and 
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1% non-essential amino acids (NEAA) (PAA, Pasching, Austria) (this medium will be 
further referred to as “Caco-2 medium”). Clone HTB37 was grown in Minimum Essential 
Medium (MEM) (Gibco, Carlsbad, CA) supplemented with 20% FBS, 1% NEAA and 
1% sodium pyruvate (PAA, Pasching, Austria). Both C2BBe1 and HBT37 clones were 
grown in T75 flasks at 37 °C and 5% CO2, and medium was changed every second day. 
Cells were sub-cultured every week with 0.1% trypsin (Sigma, Steinheim, Germany) and 
0.02% EDTA (Sigma, Steinheim, Germany). 5x105 cells (C2BBe1) or 2x105 cells (HTB37) 
were then seeded in a new T75 flask. 
THP-1: this human monocytic cell line was obtained from the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ) (Braunschweig, Germany). Cells were grown 
in T75 flasks in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Carlsbad, 
CA) supplemented with 10% FBS (this medium will be further referred to as “THP-1 
medium”) and maintained in similar conditions of temperature and CO2 as Caco-2 cells. 
THP-1 cells were differentiated to macrophage like cells by adding 5 ng/ml PMA (Sigma, 
München, Germany) to the cell culture medium. After 48 h cells were harvested and 
collected for the co-culture. 
MUTZ-3: a human monocytic cell line, which was obtained from DSMZ. Cells were grown 
in 6 well plates in α-Minimum Essential Medium (α-MEM) (Gibco, Carlsbad, CA) 
supplemented with 20% FBS and 20% conditioned medium from 5637 cells (see below). 
Cells were maintained in similar conditions as Caco-2 cells, which allowed them to acquire 
dendritic cell-like characteristics.  
5637 cells: a human bladder carcinoma cell line, which was obtained from ATCC. Cells 
were grown in T75 flasks in RPMI 1640 supplemented with 10% FBS. Medium was 
collected every second day, filtered and used as conditioned medium to prepare the cell 
culture medium for MUTZ-3 cells. Before use the conditioned medium was stored 
at -20°C. 
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2.2.2 Isolation of primary macrophages and dendritic cells 
Blood monocytes were isolated from buffy coats (blood donation service, Saarbrücken, 
Germany) and differentiated to macrophages and dendritic cells. The peripheral blood 
mononuclear cells were obtained from buffy coats by Ficoll density gradient centrifugation. 
Cells were grown in RPMI1640 supplemented with 10% human AB serum (Invitrogen, 
Carlsbad, CA, USA). After seven days primary macrophages were obtained. Primary 
dendritic cells were obtained after seven days by cultivating monocytes in the same 
medium with the addition of 25 ng/ml IL-4 and 50 ng/ml Granulocyte macrophage Colony-
Stimulating Factor (GM-CSF).  
 
2.2.3 Three dimensional triple culture of epithelial cells, macrophages and 
dendritic cells 
Differentiated THP-1 cells and MUTZ-3 cells or primary macrophages and dendritic cells 
were harvested and embedded in an 80% (w/v) solution of type I bovine collagen 
(Advanced Biomatrix, Tucson, Arizona, USA) with human AB serum and RPMI1640. 
150 µl of this solution was pipetted into the apical compartment of a transwell filter insert 
(Corning Incorporated, Acton, MA, USA) with a pore size of 0.4 µm and a filter area of 
1.12 cm2. Cells were incubated at 37 °C and 5% CO2 until the collagen layer had 
solidified. Afterwards 6x104 Caco-2 cells in 500 µl Caco-2 medium with 1% Pen/Strep 
(PAA, Pasching, Austria) were seeded on top of this collagen layer. 1.5 ml of THP-1 
medium with 1% Pen/Strep was added to the basolateral compartment. Medium was 
changed every second day. Co-cultures with the Caco-2 clone C2BBe1 were grown for 
21 days; co-cultures with the Caco-2 clone HTB37 were grown for 11 days. For 
inflammation 10 ng/ml of IL-1ß was added into the apical compartment for 48 h. 
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2.2.4 Transepithelial electrical resistance (TEER) 
TEER was measured to monitor the confluence of the Caco-2 monolayer. Cells were 
placed on a heating plate at 37 °C to avoid temperature shock-related TEER fluctuation. 
TEER was measured with a Chopstick electrode and an epithelial voltohmmeter (EVOM) 
(World Precision Instruments, Sarasota, USA). Only cell cultures presenting TEER 
values > 400 Ω*cm2 were used for experiments. 
 
2.2.5 IL-8 measurement 
IL-8 was measured with a bead-based fluorescence activated cell sorter (FACS) array. At 
several time points after inflammation 50 µl of cell culture supernatant was taken from 
apical and basolateral compartments of transwells. For measurement, a CBA Flex Set for 
IL-8 (BD Biosciences, Heidelberg, Germany) was used and samples were prepared in 
accordance with the manufacturer´s protocol. Analysis was done with FCAP array v1.01 
cytometric bead array analysis software (BD Biosciences, Heidelberg, Germany). 
 
2.2.6 Transmission electron microscopy (TEM) 
Samples were fixed by adding 2% glutaraldehyde at 37 °C in 200 mM 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), pH 7.4, directly to the 
cell culture medium at a 1:1 ratio. After 5 min the fixative and medium mixture was 
replaced with 1% glutaraldehyde in HEPES buffer at room temperature (RT) and the 
samples were incubated overnight at 4 °C. Afterwards transwell inserts were put in a 
50 ml falcon tube filled with HEPES buffer, and sent to our collaborators Dr. Urska Repnik 
and Prof. Dr. Gareth Griffiths from Oslo University, Denmark, for further preparation. For 
epon embedding, the samples were postfixed with a 2% OsO4 (EMA, PA, USA) solution 
containing 1.5% potassium ferricyanide for 1 h on ice, and stained en bloc with 
1.5% aqueous uranyl acetate (EMS, PA, USA) for 30 min. Cells were then dehydrated at 
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RT using a graded ethanol series and embedded in epoxy resin (Sigma Aldrich; St. Louis, 
MO, USA). Ultrathin sections of 70-80 nm, perpendicular to the filter plane, were cut with a 
Leica ultramicrotome Ultracut EM UCT (Leica Microsystems, Austria) and examined with 
a CM100 transmission electron microscope (FEI, The Netherlands). The images were 
recorded digitally with a Quemesa TEM CCD camera (Olympus Soft Imaging Solutions, 
Germany) and iTEM software (Olympus Soft Imaging Solutions, Germany). In addition 
2 µm thick sections were cut, stained with toluidine blue and analyzed with a widefield 
Leica DMIRBE microscope and Leica application Suite (LAC) software v 3.8 (both from 
Leica Microsystems, Germany). 
 
2.2.7 Immunostaining for confocal laser scanning microscopy (CLSM) 
THP-1 macrophages or MUTZ-3 dendritic cells were pre-stained with 2 µg/ml of 
fluorescein diacetate (FDA, Sigma Aldrich, St. Louis, MO, USA,), a cell-permeant amine-
reactive probe, in accordance with the manufacturer´s protocol. Afterwards cells were 
collected and used to seed the co-culture. Triple cultures were fixed with 
3% paraformaldehyde (PFA) in phosphate buffered saline (PBS) for 30 min at RT in the 
apical compartment and quenched with 50 mM NH4Cl, followed by 30 min incubation with 
1% bovine serum albumin (BSA) and 0.05% saponin in PBS. Afterwards the membranes 
with the collagen layer were transferred into a 24 well cell culture plate for staining. Cells 
were washed with PBS and incubated with the primary antibody (monoclonal mouse anti-
occludin, Zymed, San Francisco, CA), which was diluted 1:200 in PBS, overnight at 4 °C. 
Afterwards cells were washed with PBS and incubated for 1 h at RT with the secondary 
antibody (Alexa633 anti-mouse, LifeTechnologies, Darmstadt, Germany), which was 
diluted 1:400 in PBS. Cells were then washed and incubated for 20 min at RT with DAPI 
(LifeTechnologies, Darmstadt, Germany) in a concentration of 100 ng/ml. After staining 
the samples were mounted on slides using fluorescence mounting medium (DAKO, 
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Glostrup, Denmark). Images were acquired using a confocal laser scanning microscope 
(Zeiss, Germany) and Zen Software (Zeiss, Germany). 
 
2.2.8 Statistical analysis 
Where appropriate, data are presented as mean + standard deviation (SD). One way 
ANOVA with Holm Sidak test was used to compare results from different treatments at 
different time points. The ANOVA analysis was done with SigmaPlot 12.5 (Systat 
Software GmbH, Erkrath, Germany). Significance was assumed at p < 0.05 (*) or 
p < 0.001 (**). Individual experiments were performed in triplicate and each experiment 
was performed twice.  
 
2.3 Results 
2.3.1 Replacement of primary cells by cell lines 
As stated above, the aim of the current work was to replace the primary immune cells in 
the already established triple culture model of the inflamed mucosa [50] with cell lines. As 
epithelial cells, Caco-2 cells, clone C2BBe1, were used, as in the original model. As 
macrophages, THP-1 cells were treated with PMA for 48 h in order to promote 
differentiation into macrophage-like cells. During the process of differentiation the cells 
became adherent (Figure 2.1), and could then be harvested to be used in the co-culture 
setup. As dendritic cells, MUTZ-3 cells were used in the newly-developed model. 
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A 
 
B 
 
Figure 2.1: THP-1 cells before (A) and after (B) treatment with PMA. PMA promoted 
differentiation to macrophage-like cells was accompanied by an adherence of cells to the 
bottom of the cell culture flask. Cells are shown in 20-fold magnification. 
 
Both co-culture models were seeded and grown in parallel for 21 days until Caco-2 cells 
formed a confluent monolayer, which was monitored by measurement of TEER. After 
21 days Caco-2 cells reached TEER values between 400 and 450 Ω*cm2. The co-cultures 
were then inflamed by adding 10 ng/ml of IL-1ß into the apical compartment for 48 h. 
TEER values decreased significantly after this treatment in both triple culture models 
compared to a non-inflamed control (Figure 2.2A), which is in agreement with earlier 
studies [50], [68]. To evaluate the reversible effect of inflammation on barrier properties, 
IL-1ß was removed from the co-culture on day 23. In the absence of IL-1ß, barrier 
properties recovered as observed in relation to TEER measurement (Figure 2.2A). 
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A 
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Figure 2.2: TEER (A) and IL-8 release (B) of co-culture setups after inflammation 
with IL-1ß. Co-cultures with primary cells and cell lines were grown for three weeks and 
inflamed at day 21 (+ IL-1ß). At day 23 IL-1ß was removed (- IL-1ß). Results of both 
inflamed co-cultures were compared to TEER values of a non-inflamed co-culture with cell 
lines (A). IL-8 release was measured in co-cultures with cell lines and primary cells 0, 4, 
24 and 48 hours after inflammation with IL-1ß. Results were compared to IL-8 release 
from an inflamed Caco-2 monoculture (B) (mean ± SD, n=6 from 2 independent 
experiments, * = p<0.05, ** = p<0.001). 
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As an indicator of inflammation in the triple culture models, the pro-inflammatory cytokine 
IL-8 was measured in the cell culture supernatant. For comparison, the IL-8 release from 
a Caco-2 monoculture treated with IL-1ß was also measured. Results show that in triple 
culture models, both with cell lines and primary cells, a progressive IL-8 release after 
inflammation, reaching approximately 200 pg/ml in 48 h, occurred. However, in the 
Caco-2 monoculture only a slight IL-8 release (50 pg/ml) could be detected even 48 h 
after stimulation (Figure 2.2B). 
To understand whether macrophages and/or dendritic cells are responsible for the 
production of IL-8 in this experiment, THP-1 and MUTZ-3 cells were seeded either 
separately or together in the collagen layer, and compared to the 3D co-culture with all 
three cell lines. Cells were grown for 21 days under the same conditions as the co-culture 
models (Figure 2.3). 
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Figure 2.3: IL-8 release from different combinations of Caco-2, THP-1 and MUTZ-3 
cells. Following 21 days of culture the production of IL-8 was measured, both before and 
after inflammation with IL-1ß (mean ± SD, n=3, * = p<0.05). 
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It was shown that, when seeded separately in the collagen layer, THP-1 and MUTZ-3 cells 
were both able to produce approximately 400 pg/ml IL-8 after inflammation with IL-1ß. 
When immune cells were seeded in combination, treatment with IL-1ß resulted in an even 
greater inflammatory response with a release of 600 pg/ml of IL-8. Caco-2 cells alone 
were also able to produce IL-8 after inflammation with IL-1ß (Figure 2.2B), in accordance 
with Leonard et al [50], while the release of IL-8 was seen to be highest (800 pg/ml) when 
all three cell types were combined in a co-culture (Figure 2.3). Together these results 
show that both THP-1 and MUTZ-3 cells contribute to the inflammatory response and that 
both cell types are viable after 21 days incubation in the collagen. 
 
2.3.2 Morphological analysis of the cell line-based triple culture model with 
TEM and CLSM 
The cell line-based triple culture was also evaluated by transmission electron microscopy 
(TEM) and confocal laser scanning microscopy (CLSM). TEM pictures (Figure 2.4) 
showed a well preserved ultrastructure of the triple culture. Macrophages and dendritic 
cells are distributed within the collagen layer with the Caco-2 monolayer on top. Epithelial 
cells showed typical microvilli, desmosomes and tight junctions. Furthermore, immune 
cells in the collagen layer were well preserved and made cell contacts. Macrophages and 
dendritic cells were located in the collagen layer, as well as on top of the Caco-2 cell 
monolayer, which provides evidence for the translocation of these immune cells through 
the epithelial barrier. Both immune cell types were also observed separately. Figure 2.5 
shows that these two cell types can be distinguished based on nucleus heterochromatin 
[69]. Dendritic cells show more condensed heterochromatin than macrophages, which can 
also be observed in Figure 2.4A.  
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Figure 2.4: A microscopic overview of the non-inflamed triple culture. Caco-2 cells 
seeded on collagen, which contains immune cells. Some immune cells are observed on 
top of the epithelium (A). Detailed information regarding epithelial cells (B) was also 
obtained, including visualization of tight junctions (slim arrow) and desmosomes (block 
arrow) (C,D). Discrete immune cells could also be visualized within the collagen layer 
(Mph = macrophages, DC = dendritic cells (E)). Interaction between immune cells in the 
collagen layer were also observed (F, inserts i, ii). (A): 2 μm thick epon section analyzed 
with a wide field light microscope; (B-F): 70 nm epon sections analyzed with a 
transmission electron microscope. 
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Figure 2.5: TEM pictures of THP-1 macrophages and MUTZ-3 dendritic cells 
demonstrating heterochromatin content. Both macrophages (A) and dendritic cells (B) 
were seeded separately in the collagen layer of the triple culture and grown for 21 days. 
Dendritic cells show more heterochromatin in the nucleus than macrophages. 70 nm epon 
sections analyzed with a transmission electron microscope.  
 
Using CLSM some macrophages and dendritic cells (green) could be detected in the 
collagen layer and between or on top of the Caco-2 cells within the triple culture setup 
(Figure 2.6), which is in accordance to the TEM results (Figure 2.4). Furthermore some 
differences between the inflamed and non-inflamed triple culture could be observed: while 
the tight junctions (red), which were stained with an anti-occludin antibody, were well 
preserved in the non-inflamed model (Figure 2.6A/B), a disruption of the tight junctions 
could be seen in the inflamed culture (Figure 2.6C/D). 
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Figure 2.6: CLSM of non-inflamed and inflamed triple culture. Z-Stacks of non-
inflamed (A,B) and inflamed (C,D) co-cultures; MUTZ-3 cells (A,C) or THP-1 cells (B,D) 
were pre-stained with FDA (green), while epithelial tight junctions were stained with an 
anti-occludin antibody (red), cell nuclei are stained with DAPI (blue). Tight junctions in the 
inflamed co-culture are disrupted (C,D) and not as well defined as in the non-inflamed 
culture (A,B). Macrophages and dendritic cells (green) can be seen in between or on top 
of the Caco-2 cells in both inflamed and non-inflamed conditions. Scale bar: 50 µm. 
 
2.3.3 Improvement of the triple culture model using the Caco-2 clone HTB37 
The co-culture with the Caco-2 clone C2BBe1 required 21 days for the cells to form a 
confluent monolayer and for TEER values to reach a plateau. It was therefore aimed to 
replace these cells by epithelial cells that grow faster and need less time to form a 
confluent monolayer. Caco-2 cells from clone HTB37 are known to reach confluence in a 
shorter period of time. Therefore it was tried to seed these cells on top of the collagen 
layer instead of the Caco-2 clone C2BBe1. To find the best conditions for the new cell 
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type, different cell culture media (DMEM with 10% FBS, 1% NEAA and 1% Pen/Strep or 
MEM with 20% FBS, 1% NEAA, 1% sodium pyruvate and 1% Pen/Strep) and different cell 
numbers (20000, 40000 and 60000 cells/cm2) were used in the co-culture setup and 
compared to results with Caco-2 C2BBe1. Cells were grown for 21 days and TEER was 
measured (Figure 2.7). 
Results of TEER measurement show that the Caco-2 clone HTB37 developed higher 
TEER values after a shorter period of time as compared to the Caco-2 clone C2BBe1. 
Already after 11 days a TEER peak of 1000 Ω*cm2 was reached with HTB37 cells, which 
was seen to remain at a constant level until day 15. In the light of these results it was 
decided to use the HTB37 Caco-2 clone for further experiments with the same cell 
number (60000 cells/cm2) and the same cell culture medium (DMEM with 10% FBS, 
1% NEAA and 1% Pen/Strep) as the clone used earlier, but with the introduction of IL-1ß 
to induce inflammation after only 11 days. To be sure that the HTB37 cells showed the 
same behavior after inflammation as the C2BBe1 clone, cells were inflamed after 11 days 
and TEER and IL-8 release were measured (Figure 2.8). 
The co-culture with Caco-2 HTB37 shows the same behavior as the co-culture with 
C2BBe1: after inflammation with IL-1ß TEER values decrease and IL-8 release increases 
as pro-inflammatory marker. When IL-1ß is removed TEER values are stable and IL-8 is 
decreasing again. So for further experiments it is also possible to use Caco-2 clone 
HTB37 for the co-culture under the same conditions as Caco-2 clone C2BBe1, but with a 
shorter growth time. 
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Figure 2.7: Comparison of co-cultures with Caco-2 clones HTB37 and C2BBe1, 
using different cell culture media and different cell numbers. DMEM with 10% FBS, 
1% NEAA, 1% Pen/Strep (A) or MEM with 20% FBS, 1% NEAA, 1% sodium pyruvate, 
1% Pen/Strep (B) were used as cell culture media. Cells were seeded at 20000, 40000 
and 60000 cells/cm2; a co-culture with Caco-2 C2BBe1 60000 cells/cm2 was used as 
control. All co-cultures were grown for 21 days. 
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Figure 2.8: TEER and IL-8 release after inflammation of HTB37 co-culture and 
comparison to non-inflamed co-culture. Co-cultures were seeded with the HTB37 
Caco-2 cell clone, and allowed to grow for 11 days prior to inflammation. 
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2.4 Discussion 
In vitro models based on single cell types provide key information regarding particular cell 
type responses, e.g. to an infectious microorganism. Furthermore, cell monocultures 
represent an economic and efficient tool for a wide range of experiments. However, all cell 
culture models consisting only of one cell type do not reflect the complexity of biological 
host systems with intercellular communication. For instance, all monocultures are unable 
to reproduce active biological events, such as immune responses to pathogens or 
particles. As an alternative, co-culture models of multiple cell types, including epithelial 
cells, have been used to bridge the gap between simplistic in vitro models based on single 
cell types and the complex biological system in vivo. 
Co-culture models of various biological tissues have been widely accepted [34], [67] for 
use in several contexts, e.g. to evaluate NP toxicity when exposed to the lungs via 
inhalation [70], [71]. Regarding the intestinal epithelium, i.e. after oral ingestion, most of 
the models currently in use focus on co-cultures to study absorption, particle-cell 
translocation or particle-mucus interactions [41].  
Many research groups are working with co-culture models to get more reliable results that 
can better mimic the in vivo situation. Rothen-Rutishauser et al. for example have 
established an alveolar co-culture model of A549 epithelial cells, human monocyte-
derived macrophages and human monocyte derived dendritic cells [34], [67]. In this model 
different NPs were tested with respect to their toxicity and the results were compared to 
the same studies in monocultures. Not surprisingly, different results were found for studies 
conducted co-culture and monoculture, as the lung consists of more than one cell-type. 
This makes the use of a co-culture model more realistic and representative [68]. A co-
culture model of epithelial-like transformed cells (HeLa) together with macrophage-like 
cells (U937) has also been established by another group to investigate inflammation after 
treatment with retinoic acid and 1α,25-Dihydroxyvitam D3, which induce differentiation of 
myeloid leukemia cells into granulocytes and macrophages respectively. Macrophages 
were cultured together with the epithelial cells because they play a very important role in 
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the innate immune system [70]. It is important to keep this in mind while doing any in vitro 
experiments.  
As explained in the introduction of this thesis and mentioned above, several co-culture 
models of the intestine have also been established. For example there are several models 
employing Caco-2 cells as epithelial cells, together with mucus-producing HT29 cells as 
goblet cells and Raji B-cells, which stimulate Caco-2 cells to differentiation into M-cells. In 
some cases Caco-2 and HT29 cells are seeded on transwell filters and Raji B cells were 
seeded into the basolateral compartment, whereas in others Caco-2 and HT29 cells are 
seeded in the basolateral chamber and Raji B cells are added to the apical compartment. 
It was found that models in the first orientation show a better physiological, functional and 
reproducible model of the intestinal barrier [38]. Another established co-culture model of 
the intestine also uses mucus-producing cells. Here Caco-2 cells are cultured together 
with HT29_5M21 cells. This model showed a lower permeability than Caco-2 cells in 
monoculture, which fits better with data from in vivo experiments [71]. Another study of an 
intestinal co-culture system consisting of H4-1 small intestinal epithelial cells co-cultured 
with TLT macrophages showed that models with macrophages are better protected 
against pathogens than monocultures [74]. The review by Bermudez-Brito et al. gives 
many examples for the importance of intestinal co-culture models, especially for models 
with macrophages and dendritic cells [75].  
In the current work we focused on the development and optimization of an intestinal 
model that could mimic either healthy or inflamed conditions, which makes it an important 
tool for research on IBD. A co-culture model consisting of Caco-2 cells, macrophages and 
dendritic cells has been previously developed at our institute by Leonard and colleagues 
[50]. Macrophages and dendritic cells are used in the model because these are two cell 
types which are important for antigen possessing and presentation and furthermore for the 
activation of an immune answer [75]. However due to the expensive and time-consuming 
procedure of PBMC isolation and, even more importantly, the patient-dependent variability 
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between the different primary cell samples, it was proposed to improve the established 
model by replacing the primary cells by cell lines. The cell lines might be an option to 
establish a more robust and reproducible system. For this purpose several human 
monocytic cell lines could be used as macrophage-like cells, for example HL-60 [72] or 
U937 [73]. However, the most commonly used cell line is the monocytic leukemia cell line 
THP-1 [64]. These cells can be stimulated with PMA to induce differentiation to 
macrophage-like cells which mimic monocyte-derived macrophages in several aspects 
and behave more like monocyte-derived macrophages than other cell lines such as 
HL-60, U937 or KG-1 [66]. The THP-1 cell line has become a common model for 
macrophages in cell culture systems [74] and was therefore also used in our model. It 
could be shown that after stimulation with PMA the suspension cells adhered to the 
bottom of the cell culture flask and showed a macrophage-like shape (Figure 2.1). As 
dendritic cells the monocytic leukemia cell line MUTZ-3 was used in the model due to its 
proven suitability for use as dendritic-like cells [79]. 
After seeding of the revised triple culture model with cell line-derived immune cells, 
Caco-2 cells formed a confluent monolayer and functional tight junctions after a growth 
time of three weeks (Figure 2.2). Despite being initially seeded in the underlying collagen 
layer, it could be seen that macrophages and dendritic cells could interact with Caco-2 
cells, being located between them or on top of the epithelium (Figure 2.4, Figure 2.6). 
Interestingly this interaction did not disrupt the intercellular barrier of the tight junctions as 
shown by uncompromised TEER value measurements, which could also been observed 
in the primary cell-based model of Leonard et al. [50]. A possible explanation for this could 
be that the immune cells are trafficking into or through the Caco-2 cell layer before these 
start forming a tight barrier. Other studies have shown that THP-1 cells co-cultivated with 
Caco-2 cells induce epithelial cell death mainly due to TNF-α secretion by THP-1 cells 
[49]. However, this was not observed in our system. Furthermore, confocal images and 
TEM studies showed intact tight junctions, especially in the non-inflamed status. Real-time 
PCR studies, shown in the next chapter of this thesis, also showed that the amount of 
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TNF-α released from the triple co-culture is quite low, even after inflammation with IL-1ß 
(Figure 3.7E/F); this could be a reason why THP-1 cells do not disturb the epithelial cells 
in our model.  
After IL-1ß-induced inflammation, the 3D co-culture model showed a decrease in TEER 
values (Figure 2.2A). This effect was reversible when IL-1ß was removed, which is in 
agreement with observations of the previous model based on primary cells [50]. 
Inflammation leads to a loss of the epithelial barrier function due to the opening of tight 
junctions [76]. Changes in the expression pattern of different tight junction proteins as for 
example claudin 4, 5 or 8 could be responsible for this effect [77], [78]. Other groups have 
also reported significantly decreasing TEER values after treatment of Caco-2 cells with 
the inflammation-inducing agent LPS [79], corroborating our data.  
Inflammation of the co-culture resulted in a greater increase of IL-8 release in comparison 
to the epithelial monoculture (Figure 2.2B), probably as a result of the presence of 
immune-competent cells in the co-culture. The level of cytokine production was also 
comparable between models containing cell lines or primary immune cells. MUTZ-3 and 
THP-1 cells seeded separately already release IL-8 after an inflammable stimulus 
(Figure 2.3). When they are seeded together the release is even higher although it does 
not reach the additive level, which shows that the two cell types influence each other in 
that way that they do not have to produce as much IL-8 as when they are seeded 
separately.  
Many experiments with nanomaterials in co-culture models have shown a clear difference 
to the results of monocultures [68], [69], [70]. Immune-competent cells may influence 
epithelial barrier properties during inflammation as shown in studies using endothelial cells 
[80]; however in our model this was not observed. Nevertheless, immune cells are a very 
important factor in inflammation models because of the release of pro-inflammatory 
cytokines to measure the inflammation status. 
Following indications that the replacement of primary cells with cell lines did not result in 
significant changes in the behavior or characteristics of the triple culture model, the next 
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step was to attempt to further optimize the model by reducing the growth time of the cells 
prior to model inflammation and/or further use. As mentioned, the Caco-2 clone C2BBe1 
cells need 21 days to form a confluent monolayer. Within such a span of time the immune 
cells within the co-culture could die and in addition, the danger of contamination with 
bacteria is considerable. Therefore, an alternative Caco-2 clone (HTB37) was used. 
Previous comparisons of different Caco-2 clones (TC7, PD7, PF11) have shown that 
some differences may occur, although all the clones are of the same cell line. Several 
metabolic capabilities such as cell viability or fatty acid and cholesterol uptake were 
investigated, and it was found that the clones TC7, PD7 and PF11 show different results 
[81]. As well as different metabolic behavior between clones, it was also shown that 
different batches from the same clone showed different morphologies [82] necessitating 
consistent use of the same passage numbers for experiments.  
The clone C2BBe1 is always used as Caco-2 cell line in our laboratories - and was also 
used in the first co-culture model with primary immune cells - which was the reason why it 
was our first choice. Experiments with the clone HTB37 however showed that these cells 
need a shorter growth time under the same conditions with the same cell culture medium 
as previously (containing 10% FBS), and that they build higher TEER values in a shorter 
time period (Figure 2.7). By using an even higher amount of FBS (20%) in the culture 
medium, HTB37 cells were seen to grow even faster, however TEER values were seen to 
decrease at an earlier time point. As higher TEER values in general were seen with 
HTB37 cells, a greater decrease in TEER values could be observed following 
inflammation with IL-1ß; as for the previous model utilizing C2BBe1 cells however TEER 
values were seen to recover after removal of IL-1ß. This is seen as a considerable 
advantage of using HTB37 cells, as the effects of inflammation may be even better 
monitored. Furthermore, IL-8 release when using HTB37 cells was comparable to that 
observed in the model using the Caco-2 clone C2BBe1. With the HTB37 Caco-2 clone it is 
therefore considered that the model is even more useful for high throughput studies 
because more experiments can be done in less time.  
 Chapter 2: Replacement of primary cells by cell lines 
45 
 
2.5 Conclusion 
The previously established co-culture model of the inflamed mucosa is a useful in vitro 
model for IBD research because both inflammation of this model with IL-1ß and healing of 
the model following IL-1ß removal are possible. The replacement of primary immune cells 
by the cell lines THP-1 and MUTZ-3, as shown in the current chapter, resulted in a more 
robust system useful for higher throughput assays, without any effect on the model 
immunocompetence or epithelial cell differentiation. Furthermore, this cell line-based 
model has the advantage of being less time consuming to prepare and less variable with 
respect to model behavior and experimental results than models based on primary cells 
obtained from blood samples of different patients. By using the Caco-2 clone HTB37 
instead of C2BBe1 the growth time of the cells could be reduced from 21 to 11 days, even 
further increasing the experimental throughput and output capacity. Another improvement 
is that these Caco-2 cells build higher TEER values, which makes it easier to monitor the 
inflammation of the model.  
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3 Cytotoxicity measurements of nanoparticles in the cell line-
based co-culture model 
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3.1 Introduction 
Engineered nanomaterials (ENs) are commonly employed in food packaging or as 
additives in various food products, meaning that the chance of unintended human 
exposure is relatively high. Increased exposure to particulate matter has previously been 
identified as one of the main environmental factors associated with autoimmune and 
inflammatory diseases, especially those involving the intestine [83], [84]. For instance, 
studies show that exposure to microparticles has been linked to the occurrence of IBD, in 
particular Crohn´s disease [85]. Food often contains many non-nutrient microparticles like 
soil and dust or food additives, which can be taken up by mucosal cells, resulting in 
inflammatory reactions [86]. NPs can be inhaled, e.g. carbon NPs from laser printers [87], 
but also swallowed, the latter case being reported to cause diarrhea and histological 
alterations typical of Crohn´s disease [88]. Thus there is an urgent need to understand 
better the interaction between nanomaterials and the intestinal mucosa, especially in the 
context of local inflammatory events and diseases.  
ENs are also used in innovative drug delivery systems as they can target drugs to their 
site of action and can protect the cargo from degradation [89]. Therefore, it is essential to 
thoroughly characterize the safety of ENs. However, the complexity of biological systems 
makes it difficult to precisely assess the impact of nanomaterials. This holds true in 
particular for animal models of biological systems, which due to their complexity are 
essentially “black boxes”, difficult to handle and also posing ethical challenges. Therefore, 
there is a need for advanced cell- and tissue-based in vitro models that allow for studying 
the effects of NPs under well-controlled conditions by monitoring endpoints of clinical 
relevance. Currently, the enterocyte cell line Caco-2 is a well-established model for the 
human intestinal barrier. A number of in vitro studies have used the Caco-2 cell line to 
assess cytotoxicity in the GI as well as systemic uptake after oral exposure [90], [91]. 
However, the complex physiology of the intestinal mucosa is insufficiently modeled with 
only one cell type, which might explain the limited correlation between in vivo and in vitro 
studies achieved to date [92]–[94].  
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As already mentioned in the previous chapters, one obvious shortcoming of the Caco-2 
monoculture model is the lack of immune-competent cells, which are clearly important in 
the context of inflammatory disorders such as IBD. Interactions between nanomaterials 
and immune cells can lead to inflammatory reactions with pro-inflammatory cytokine 
release and cytotoxic effects [47]. NP uptake by immune cells is an important issue 
related to nanotoxicity. Several NP properties, including the physicochemical properties of 
size and surface charge, might influence cellular particle uptake. Studies show that 
particles with cationic or anionic surface charges are more attractive to phagocytes than 
neutral particles [95], and it is known that particles below 200 nm in diameter show poor 
uptake by macrophages in comparison to particles between 0.5 and 3 µm in size [96].  
Several groups have used in vitro cell models to evaluate NP toxicity either in 
monocultures [90], [91], [97] or in co-cultures [67], [68]. Indeed, in vitro models containing 
two or more types of cells, able to interact with each other and with nanomaterials, seem 
to be more able to capture the complexity of the in vivo situation. As mentioned, our 
research group has previously established a 3D in vitro model of the intestinal mucosa 
consisting of the Caco-2 intestinal epithelial cell line with primary blood derived dendritic 
cells and macrophages embedded in a collagen type I gel [50]. This model has been 
shown to exhibit relevant barrier properties for studying NP translocation. It also appears 
to reflect typical pathophysiological changes that are observed in the state of inflammation 
in vivo, such as decreased epithelial barrier function, increased production of pro-
inflammatory cytokines and an alleviation of such symptoms when anti-inflammatory 
formulations for the treatment of IBD were applied [51]. However, this model suffered from 
a relatively high variability and low throughput potential as well as difficulties in 
standardization, due to its use of primary-derived immune cells. Therefore, the model was 
modified, as described in the previous chapter, to rather include cell line-derived 
macrophages and dendritic cells. Such a substitution was not seen to compromise the 
ability of the model to build an intact permeation-relevant barrier or respond to 
inflammatory stimuli [103].  
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Figure 3.1: Pathways for NP-induced toxicity (Manke et al. [104]). 
 
The aim of the work in the current chapter was to use this improved, cell line-based in 
vitro model consisting of Caco-2, THP-1 and MUTZ-3 cells to assess the cytotoxicity of 
engineered NPs. It is known that NPs from various materials induce oxidative stress in the 
form of reactive oxygen species (ROS) [105], [106]. ROS generation can lead to e.g. 
inflammation, cell death or mitochondrial dysfunction as shown in Figure 3.1 [104]. 
Several of these effects are investigated in our experiments. For this purpose silver (Ag), 
titanium dioxide (TiO2) and gold (Au) NPs were used. These particles were chosen based 
on their relevance for oral exposure as well as for their use in other toxicological studies: 
Ag NPs are frequently used in commercial products because of their antimicrobial 
properties. Such products include cosmetics, textiles and wound dressings, but also food 
packaging, in which their function is to enhance the shelf life of products. As such they 
may be released into food and swallowed by humans. A number of studies have 
described Ag NPs as being able to induce toxicity in a number of different species, and 
uptake by the intestine has been reported in animal models [98], [99]. As for other 
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nanomaterials, the toxicity of Ag NPs depends on their concentration and size as uptake 
of the particles is influenced by both parameters. Furthermore, smaller Ag NPs release 
more Ag+ ions, which have been controversially discussed as being the main effectors in 
Ag NP associated toxicity [100]. 
TiO2 NPs are present in many kinds of food, especially sweets such as candies and 
marshmallows. Children consume more of these kinds of food than adults, therefore 
having higher exposure rates to such particles [101]. Additionally, TiO2 NPs serve as 
whitening agents in toothpastes.  
Au NPs may also be included in toothpastes and packaging [102], but 
nanomedicines/diagnostics and nanoelectronics are more likely sources of application and 
so exposure. Due to their bright near-infrared fluorescence alone or in combination with 
e.g. chemotherapeutics in complex theranostic systems, they are used as imaging agents. 
The toxic potential and uptake pathway of Au NPs remains unclear [103] 
 
3.2 Materials and Methods 
3.2.1 Nanoparticles (NPs) 
NM300 Ag NPs with a size of < 20 nm, PVP capped, and NM101 TiO2 NPs with a size of 
7-10 nm were purchased from JRC (Joint Research Centre, Ispra, Italy). Au NPs in two 
different sizes, 15 and 80 nm, were kindly provided by Dr. Wolfgang W. Kreyling, Institute 
of Lung Biology and Disease, Helmholtz Zentrum, Munich. 
 
3.2.2 NP preparation and characterization 
For TiO2 and Au NPs, stock solutions were prepared by suspending 76 mg of the 
respective NPs in MilliQ water with 2% FBS to a final concentration of 2.56 mg/ml. Ag NPs 
were provided at 10% (w/w) dispersed in a viscous mixture of water (75%) with 
7% ammonium nitrate as stabilizing agent and 4% Tween20 and polyoxyethylene glycerol 
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trioleate as emulsifiers. A protocol from the ENPRA project (www.enpra.eu) was used to 
prepare a stock solution of Ag NPs. In accordance with this protocol 100 mg of Ag NP 
solution were dispersed in 38 ml water containing 2% FBS to achieve a final concentration 
of 2.56 mg/ml. All the stock solutions were sonicated for 15 min in an ultrasonic bath 
(Bandelin electronic, Berlin, Germany) at 200 W. NPs were then further diluted in Caco-2 
medium (described in chapter 2) to achieve concentrations between 0.0001 and 1 mg/ml. 
Following the dilution in medium, the NPs were sonicated again for 15 min before use in 
the experiments. For every experiment NPs were freshly dispersed, and the same 
dispersion protocol was used. 
For TiO2 and Au NPs, the hydrodynamic particle diameter was determined via dynamic 
light scattering with the Malvern Zetasizer® nano (Malvern Instruments, Herrenberg, 
Germany). Particle size and polydispersity index (PDI) were determined 0, 1, 2, 4, 6, 8 
and 24 h after preparation of the respective dilution. The dilutions were kept at RT 
protected from light and were sonicated for 15 min before the measurement. Two 
independent samples were measured three times at each time point to calculate mean 
and SD. 
For Ag NPs size distribution and stability were investigated with a NanoSight® LM10 
instrument (Malvern Instruments, Herrenberg, Germany). This measurement is also based 
on dynamic light scattering, but uses single particle tracking analysis. Two particle 
concentrations were tested and mean particle diameter and width of the distribution were 
measured three times. 
For TiO2 and Ag NPs concentrations between 1.25 and 625 µ/cm
2 were tested, for Au 
NPs concentrations between 0.156 and 80 µg/cm2 (Table 3.1). These concentrations were 
used for the following cytotoxicity studies with the different cell culture models.  
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Table 3.1: Nanoparticle concentrations employed in cytotoxicity studies with the 
different cell culture models. 
Ag, TiO2 Au 
 
[µg/cm2] [µg/ml] [µg/cm2] [µg/ml] 
625 1000 80 128 
312.5 500 40 64 
156.25 250 20 32 
78.125 125 10 16 
39.065 62.5 5 8 
19.53 31.25 2.5 4 
9.77 15.625 1.25 2 
5 8 0.625 1 
2.5 4 0.3125 0.5 
1.25 2 0.15625 0.25 
 
3.2.3 Cell culture 
Cells were cultured as described in section 2.2.1. The Caco-2 clone C2BBe1 was used for 
the following experiments. 
 
3.2.4 Triple culture of the intestinal mucosa 
The triple culture was set up as described in section 2.2.3. NPs were added to the apical 
compartment after removal of IL-1ß. Cells were incubated with the particles for 24 h as 
shown in Figure 3.2 until the endpoints were measured. 
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Figure 3.2: Experimental setup for NP toxicity studies using the triple culture 
model. 
 
3.2.5 Cell viability measurement via lactate dehydrogenase (LDH) and Alamar 
Blue assay 
To test NP toxicity, Caco-2 cells were seeded at 2x104 cells/well in 96 well plates and 
grown for 7 days. Cells were incubated with various concentrations (Table 3.1) of the 
different NPs for 24 h at 37 °C and 5% CO2. Following this incubation period, 100 µl of the 
supernatant was collected and LDH release was measured via an LDH detection kit 
(Roche, Mannheim, Germany), in accordance with the manufacturer´s protocol. Briefly, 
this involved incubation of supernatant samples with the LDH reagent in the dark for 3 min 
at RT, followed by measurement of excitation at 492 nm with a plate reader (TECAN, 
Männedorf, Switzerland). For the Alamar Blue assay (which indicated cell metabolic 
activity), the adherent cells were washed with PBS, and fresh cell culture medium and 
10% of Cell Titer Blue Reagent (Promega, Mannheim, Germany) were added. Cells were 
incubated at 37 °C and 5% CO2 and the formation of violet Resofurin salt was measured 
at 590 nm using a plate reader after 30 and 150 min. The specific metabolic activity was 
calculated as: (Abs 2h30’- Abs 30’)/120’. Sample data was normalized to the non-treated 
medium control. 
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The viability of the inflamed and non-inflamed triple culture incubated with different 
concentrations of NPs was also evaluated with LDH and Alamar Blue assays, as 
described above. 
 
3.2.6 Influence of Ag ions on cell viability 
The impact of Ag ions on cell viability was assessed using the LDH assay, as described in 
section 3.2.5. Caco-2 cells were incubated with AgNO3, Ag NPs and supernatant from 
which intact Ag NPs were removed. Ag NPs with a concentration of 156.25 µg/cm2 were 
dispersed in cell culture medium, incubated for 24 h at 37 °C and ultracentrifuged 
(450,000 g). Supernatant was collected and Caco-2 cells were incubated with this for 
24 h. As controls cells were also incubated with Ag NPs and AgNO3 in equivalent 
concentrations under similar conditions.  
 
3.2.7 Transmission electron microscopy (TEM) 
Inflamed and non-inflamed co-cultures were incubated with Ag NPs in a concentration of 
156,25 µg/cm2 and 15 nm Au NPs in a concentration of 20 µg/cm2 for 24 h. Afterwards 
samples were prepared for TEM investigations as described in section 2.2.6. 
 
3.2.8 TEER 
TEER measurement as an indicator of cell culture barrier function was performed before 
and 24 h after the incubation with NPs as described in section 2.2.4. 
 
3.2.9 Cytokine measurement (IL-8) on the protein level via FACS 
The production of IL-8 as an indicator of inflammation was measured before and 24 h 
after the incubation with NPs as described in section 2.2.5. 
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3.2.10 Cytokine measurement (IL-8 and TNF-α) on the mRNA level via Real-time 
PCR 
Relative changes in mRNA transcription of the pro-inflammatory marker IL-8 after 
incubation with different NPs were determined using a quantitative real-time polymerase 
chain reaction (qRT-PCR). Cells were incubated with NPs for 24 h, collected and lysed. 
Total RNA was then extracted from the cells with a QIAshredder (Qiagen, Hilden, 
Germany) and RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. RNA amount was measured using a photometer (Eppendorf, 
Hamburg, Germany). A 500 µg amount of RNA was then transcribed into cDNA with a 
QuantiTect Transcription Kit (Qiagen, Hilden, Germany). 
Quantitative PCR was conducted using a QuantiTect Probe PCR Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Three replicates were measured 
for every sample. 35 cycles were measured (10 seconds: 94 °C, 30 seconds: 60 °C); 
β-actin was used as a housekeeping gene. Sequences of primers and probes employed 
are shown in Table 3.2.  
 
 
 
 
 
 
 
 
 
 Chapter 3: Cytotoxicity measurements of nanoparticles 
56 
 
Table 3.2: Sequences of primers and probes for quantitative Real-Time PCR 
 Sense Antisense Probe 
Human β-actin TGC GTG ACA TTA 
AGG AGA AG 
GTC AGG CAG CTC 
GTA GCT CT 
FAM-CAC GGC TGC 
TTC CAG CTC CTC-
BHQ1 
Human IL-8 TGC CAG TGA AAC 
TTC AAG CA 
ATT GCA TCT GGC 
AAC CCT AC 
FAM-TCA ACA CTT 
CAT GTA TTG TGT 
GGG TCT G-BHQ1 
Human TNFα CTC CAC CCA TGT 
GCT CCT CA 
CTC TGG CAG GGG 
CTC TTG AT 
FAM-CAC CAT CAG 
CCG CAT CGC CGT 
CTC-BHQ1 
 
 
3.2.11 Statistical analysis 
Where appropriate, data are presented as mean + standard deviation (SD). One way 
ANOVA with Holm Sidak test was used to compare results from different treatments at 
different time points. The ANOVA analysis was done with SigmaPlot 12.5 (Systat 
Software GmbH, Erkrath, Germany). Significance was assumed at p < 0.05 (*) or 
p < 0.001 (**). Individual experiments were performed in triplicate and each experiment 
was performed twice. EC50 values were calculated with Sigma Plot 12.5. 
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3.3 Results 
3.3.1 NP characterization 
Engineered NPs were evaluated according to their dispersion behavior. The two Au NP 
batches could be easily dispersed in the culture medium at the tested concentrations. The 
measured hydrodynamic diameter was slightly larger than the nominal diameter supplied 
by the manufacturer (Table 3.3) with a PDI < 0.1, indicating a narrow size distribution even 
at high concentrations of 0.1 mg/ml. The particles did not agglomerate in the cell culture 
medium, but a thin particle corona was likely formed by adsorption of proteins or other 
components from the Caco-2 medium.  
For TiO2 particles, the dispersibility was very poor in MilliQ water, but could be improved in 
cell culture medium due to the high FBS/protein concentration and resulting steric 
stabilization of the particle dispersion. Nevertheless, agglomerates between 700 and 
1200 nm were still formed, and measured particle samples showed a high PDI (> 0.4). 
Ag NPs could not be evaluated in the Zetasizer via dynamic light scattering due to 
interference with the laser. Instead the size distribution and stability of the particle 
dispersion were determined using single particle tracking analysis (NanoSight, Malvern 
Instruments, Herrenberg, Germany), which employs a different laser wavelength. The 
mean hydrodynamic diameter of the particles was found to be 120 nm; this value was 
considerably higher than manufacturer-supplied value < 20 nm, hinting at particle cluster 
formation together with serum proteins. Particle size distribution was however 
monomodal, and no agglomeration was observed within 24 h of storage in cell culture 
medium at 4 °C (Table 3.3).  
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Table 3.3: Dispersion behavior of ENs in DMEM cell culture medium at 0.1 mg/ml 
after 1 h of incubation 
NPs Mean hydrodynamic 
diameter [nm] 
PDI 
Au 15 51 ± 6 0.04 ± 0.01 
Au 80 116 ± 5 0.04 ± 0.02 
TiO2 896 ± 133 0.42 ± 0.14 
Ag 120 ± 4 NA 
 
 
3.3.2 Cell viability measurement – LDH and Alamar Blue assay 
After incubating Caco-2 monocultures and inflamed and non-inflamed co-cultures with the 
various NP concentrations, cell culture supernatant samples were collected to measure 
LDH release as an indication of cell damage. Furthermore, NP-treated cells were 
incubated with fresh medium and Cell Titer Blue reagent was added to measure the 
metabolic activity of the cells via the Alamar Blue assay. Figure 3.3 shows the results for 
both assays after incubation of Caco-2 monoculture, inflamed and non-inflamed co-culture 
for 24 h with 625 µg/cm2 of Ag and TiO2 NPs and 80 µg/cm
2 of both 15 nm and 80 nm 
Au NPs. 
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Figure 3.3: Results of LDH (A) and Alamar Blue (B) assay after incubation of Caco-2 
monoculture, inflamed and non-inflamed co-culture with the highest tested NP 
concentrations (mean ± SD, n=6 from 2 independent experiments, * = p<0.05, 
** = p<0.001). 
 
Incubation with the highest employed concentration of both types of Au NPs did not affect 
cell viability and there was no difference between the results of the Caco-2 mono- and co-
culture setups, regardless of the state of inflammation. In contrast, the highest employed 
concentration of Ag NPs induced significant toxicity after 24 h. The Caco-2 monoculture 
was more sensitive to Ag NPs than the co-culture model. Looking at Figure 3.3A, it looks 
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like there is a significant influence of the state of co-culture inflammation on Ag NP-
induced cytotoxicity, but not in Figure 3.3B. For TiO2 NPs the LDH assay does not show 
any toxic effects. However, the results of the Alamar Blue assay show that viability of the 
cells decreases in the case of the inflamed co-culture.   
To further investigate the toxic effects of the Ag NPs, these were studied at various 
concentrations which are shown in Table 3.1. Based on the results both from the LDH and 
Alamar Blue assay (Figure 3.4) the Caco-2 monoculture was significantly more 
susceptible than the co-culture to cytotoxic damage by Ag NPs, while there was at least a 
slightly increased susceptibility of the inflamed compared to the non-inflamed co-culture. 
LDH EC50 values from Caco-2 monoculture (85 µg/cm2) and inflamed (216 µg/cm2) or 
non-inflamed (364 µg/cm2) co-culture also confirm this result. 
The LDH assay was also used to investigate whether the presence of Ag ions was 
responsible for the toxic effect of Ag NPs (Figure 3.5). Incubation of cells with AgNO3 
containing liberated Ag+ was confirmed to be equally toxic to Caco-2 cells as Ag NPs. In 
contrast, no LDH release was measurable in cell cultures treated with the Ag NP-free 
supernatant, indicating that Ag NP toxicity is not caused by released Ag+ ions present in 
cell culture supernatants. 
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Figure 3.4: LDH assay and Alamar Blue assay after incubation of Caco-2 
monoculture, inflamed and non-inflamed co-culture with different concentrations of 
Ag NPs. LDH release (A) and mitochondrial activity (B) were measured for all Ag NP 
concentrations in all cell culture setups (mean ± SD, n=6 from 2 independent 
experiments). 
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Figure 3.5: Influence of Ag ions on cell viability. LDH assay was performed in Caco-2 
monoculture incubated with AgNO3, Ag NPs and supernatant from which intact Ag NPs 
were removed (mean ± SD, n=3, * = p<0.05, ** = p<0.001 relative to cells incubated with 
NP-free supernatant). 
 
3.3.3 Assessment of Caco-2 cell integrity via TEER measurement  
TEER of cell cultures was measured before and 24 h after NP incubation in order to 
assess the effect of NPs on barrier properties (Figure 3.6). Barrier function was seen to 
remain intact after incubation with TiO2 (Figure 3.6B) or Au (Figure 3.6C/D) NPs, even 
following incubation of cells with high concentrations of NPs. However, in the case of both 
mono- and co-cultures, treatment of cells with Ag NPs at concentrations greater than or 
equal to 156.25 µg/cm2 resulted in disruption of the epithelial barrier, as indicated by a 
steep drop of the TEER (Figure 3.6A). The monoculture was seen to be the most sensitive 
to Ag NPs followed by the inflamed and the non-inflamed co-culture, with a decrease in 
TEER already observable at the even lower concentration of 78.125 µg/cm2. 
With the highest Ag NP concentration (625 µg/cm2), TEER values showed an abrupt 
decrease in both mono-and co-cultures, to extremely low levels similar to those exhibited 
by cells incubated with 1% TritonX, which served as a positive control (data not shown).  
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Figure 3.6: TEER values of Caco-2 monoculture, inflamed and non-inflamed co-
culture after incubation with different concentrations of the NPs. Cells were 
incubated for 24 h with Ag (A), TiO2 (B), 15 nm Au (C) and 80 nm Au (D) NPs. TEER was 
measured before and after incubation. Values are shown as percentage of TEER values 
after incubation relative to TEER values before incubation with NPs (mean ± SD, n=6 from 
2 independent experiments, ** = p<0.001 relative to TEER values of non-treated controls 
(not shown)). 
 
3.3.4 Impact of NPs on inflammatory response 
In order to identify possible sub-lethal but nevertheless potentially damaging effects on the 
epithelial cells, inflammatory responses were monitored during cellular exposure to NPs 
by measuring the secretion of pro-inflammatory cytokines. For this purpose the apparently 
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non-toxic 15 nm Au NPs were chosen for investigation and compared with the evidently 
more toxic Ag NPs.  
Co-cultures as well as Caco-2 monocultures were exposed to Ag and 15 nm Au NPs for 
24 h. TiO2 and 80 nm Au NPs were also initially tested, but production of neither IL-8 nor 
TNF-α could be detected (data not shown). The inflammatory response to Ag und 15 nm 
Au NPs was therefore evaluated by monitoring the stimulation of IL-8 on a protein level 
(Figure 3.7A/B), as well IL-8 (Figure 3.7C/D) and TNF-α (Figure 3.7E/F) on a 
transcriptional level. In Caco-2 monoculture a slight increase in IL-8 release was only 
observed with the highest Ag NP concentration employed. However in both the inflamed 
and non-inflamed co-cultures, IL-8 release was observed already after incubation with the 
lowest tested concentration of Ag NPs (Figure 3.7A). This indicates that Ag NPs induce 
inflammatory reactions even at concentrations which are not toxic to the cells. With 
respect to the relative induction of inflammation with Ag NPs, again, significant differences 
between the inflamed and non-inflamed co-culture state were observed. Surprisingly the 
non-inflamed co-culture released more IL-8 than the inflamed one when exposed to Ag 
NPs. The results with Ag NPs from real-time PCR experiments agreed well with protein 
expression data (Figure 3.7C). TNF-α measurement showed similar results as seen with 
IL-8, although a relatively lower expression of TNF-α was oberved (Figure 3.7E). 
Incubation of Caco-2 cells in monoculture with low concentrations of Au NPs did not 
induce a significant increase of IL-8 production at any tested concentration. In the co-
cultures a considerable release of IL-8 was observed, however the levels were 
approximately ten times lower than those observed with Ag NPs. Again the stimulation 
was concentration-dependent, but in this case the inflamed co-cultures released more IL-8 
than the healthy ones (Figure 3.7B). In the co-culture models a release of TNF-α was also 
observed, however this only reached appreciable levels at the highest employed 
concentration of Au NPs (Figure 3.7F). 
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Figure 3.7: IL-8 release on protein (A,B) and transcriptional level (C,D) and TNF-α 
release on transcriptional level (E,F) after 24 h incubation of Caco-2 monocultures, 
inflamed and non-inflamed co-cultures with different concentrations of Ag and Au 
NPs. Cells were incubated for 24 h with Ag (A/C/E) or 15 nm Au (B/D/F) NPs (mean ± SD, 
n=6 from 2 independent experiments, * = p<0.05, ** = p<0.001). 
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3.3.5 Uptake of NPs 
To evaluate the internalization of NPs, TEM analysis were performed with co-cultures 
after 24 h incubation with NPs. TiO2 NPs could not be included in this experimental setup 
as samples for the TEM have to be cut with a diamond knife, which was not able to cut 
these particles. TEM images of cells incubated with Ag NPs could not be analyzed with 
respect to particle uptake, as the used concentration of 156.25 µg/cm2 of Ag NPs was 
seen to be toxic (as confirmed by cytotoxicity studies) and resulted in the death of cells in 
the co-culture set-up. The 15 nm Au NPs were however found to be taken up by the cells. 
No particles could be found in macrophages or dendritic cells, but it could be shown that 
the NPs were taken up by Caco-2 cells in the co-culture independent of the state of 
inflammation (Figure 3.8). 
 
Figure 3.8: TEM images of Au NPs (15 nm) uptake by Caco-2 cells in non-inflamed 
(A,B) and inflamed (C,D) co-culture following 24 h incubation. 
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3.4 Discussion 
Assessment of toxicity of nanomaterials is of huge concern, as a significant fraction of the 
population comes into daily contact with NPs. Furthermore, the field of nanotechnology is 
advancing at an increase rate, yet still not enough is known about the danger of 
nanomaterials. Many examples shown in the review by Arora et al. [104] illustrate how 
important thorough nanotoxicological characterization is, in order to avoid potential 
adverse effects of nanomaterials. By using appropriate in vitro models the toxicity of 
nanoparticles can be tested and thereby the safety of nanomaterials can be increased.  
In the light of the importance of toxicity testing and the use of appropriate, representative 
models to do this, the aim of the study in this chapter was to investigate the toxicity of 
different ENs in different cell culture setups. The results from a Caco-2 monoculture and 
inflamed and non-inflamed co-cultures of the intestinal mucosa were compared to 
determine if the used co-cultures showed different behavior in presence of the NPs in 
comparison to the monoculture, and thus potentially provide data more relevant to the in 
vivo situation than the standard Caco-2 monoculture. 
Cytotoxicity testing in cell cultures is a very important tool in toxicology [105]. Caco-2 cells 
are considered to be the most often used model for the human intestine, in the light of 
their previously mentioned morphological and biochemical similarities to small intestinal 
enterocytes: they grow in a monolayer, show a cylindrical polarized morphology with 
microvilli on the apical side and tight junctions between cells, and express small intestinal 
hydrolase enzymes [106]. As such, Caco-2 cells have been used as a model of the 
intestinal mucosa in several toxicity studies, not just with NPs, but also with numerous 
other compounds. However, the in vitro-in vivo correlation in these experiments is often 
not satisfactory [92]–[94]. The limitation of the Caco-2 monoculture is that the interaction 
between different cell types, as occurs in vivo, is missing; for example immune competent 
cells, which play a very important role in the reaction after exposure to NPs or other toxic 
compounds, are absent. Therefore, the currently employed co-culture model with Caco-2 
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cells, macrophages and dendritic cells was established. In this model the influence of 
immune-competent cells (e.g. possible protection of epithelial cells) on the results of 
cytotoxicity measurements could be assessed. Another advantage of such a model is that 
it is possible to induce an inflammation, creating possibilities for testing in relevant disease 
models as for example IBD.  
To assess the toxicity of different ENs, Caco-2 monocultures as well as inflamed and non-
inflamed co-cultures were incubated with the NPs for 24 h. Cytotoxicity was measured via 
membrane damage (LDH release), mitochondrial activity (Alamar Blue assay) and 
integrity of the cell monolayer (TEER); inflammation was also assessed via measurement 
of release of pro-inflammatory markers (IL-8 and TNF-α) on both transcriptional (real-time 
PCR) and protein (FACS) levels. Some similarities could be seen in Caco-2 monoculture 
testing in comparison to the inflamed and non-inflamed co-cultures. However, some 
interesting differences between the cell culture setups were also found.  
To explore the possible differences in toxicity triggered by various ENs, we studied the 
interactions of Au, TiO2 and Ag NPs with the 3D co-culture and with Caco-2 monolayers. 
For Au NPs some studies have shown that they are not toxic; however, in contrast, other 
studies have found a low toxicity of Au NPs [107]–[109]. It is possible that the toxicity 
depends on the size of the particles [110]. Here two differently-sized Au NPs were used, 
15 and 80 nm, but no toxic effect in response to incubation with these NPs was detected 
in any cell culture model (Figure 3.3). However IL-8 gene expression was slightly 
increased after exposure to the 15 nm Au NPs in the triple culture models (Figure 3.7). 
This is in agreement with literature, where it has been shown that Au NPs induce an 
inflammatory response also in a co-culture model of the human airways [60]. In vivo 
assays have also shown a significant expression of pro-inflammatory markers such as 
IL-6, IL-1ß [111] or, as in our case, TNF-α [60] after treatment with different Au NPs.  
Our observations that Au NPs were able to induce inflammatory responses that were 
evident only in the co-culture models is in agreement with other studies, supporting the 
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use of more complex in vitro systems to investigate in-depth interactions between NPs 
and biological systems. Differences in responses of co-cultures and monocultures of 
epithelial cells (H441) and endothelial cells (ISO-HAS-1) [105] have been documented in 
literature, while further studies have highlighted clear differences between the interaction 
of nanomaterials with co-culture and monoculture models [71], [84]. It has also been 
shown previously that a co-culture system with epithelial and immune cells, such as 
macrophages, dendritic cells or mast cells, can exhibit an amplified inflammatory 
response following contact with particles in comparison to monoculture models [112]. In 
our model this amplified effect can be explained by the presence of the macrophages and 
dendritic cells, which are both responsible for the cytokine release, which was shown in 
Figure 2.3. The measurement of interleukins as readouts of inflammatory NP interactions 
with cells allows for the investigation of other cellular responses besides membrane 
permeability and metabolic activity changes. Indeed, interleukins are important biomarkers 
for inflammation also in the in vivo situation as shown for example in the high release of 
IL-8 in the GI tract of IBD patients [113]. Therefore the inflammatory response, and 
cytokine measurement as a reliable endpoint for this, is an important parameter to be 
addressed in the interaction between NPs and living systems. As such it should be 
included in safety testing of NPs and nanoparticulate pharmaceuticals, as, as seen in the 
current work in relation to experiments with Au NPs, potentially harmful inflammatory 
effects can occur even at subtoxic concentrations.  
When the uptake of Au NPs by the cells in the 3D co-culture was evaluated, it was found 
that these particles were mostly internalized by Caco-2 cells rather than by macrophages 
(Figure 3.8). This effect could possibly be due to the 24 h incubation time used for the 
experiment – while the immune cells could have in fact taken up the particles, particle 
digestion could have already taken place by the time of TEM investigations. Another 
reason could be that the collagen layer is a limiting factor in the co-culture system. It was 
shown in the previous chapter that the immune cells are able to move through the 
collagen to get between or on top of the Caco-2 cells. However, it is not proven if the NPs 
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are able to similarly get through the collagen layer, meaning that perhaps not many 
immune cells are able to get in contact with the nanomaterials.  
NM101 TiO2 NPs did not induce any notable toxic effects or inflammation in either 
monoculture or triple culture models in the current work (Figure 3.3, Figure 3.6, 
Figure 3.7), which is a good sign since TiO2 NPs are often found in food or tooth-paste 
[114] and can easily reach the human intestine. Other studies have shown a low toxicity of 
differently-sized TiO2 NPs to mouse macrophages [115] and epithelial lung cells [116] in 
monoculture models; a study utilizing a co-culture model of the human airway wall with 
macrophages, dendritic cells and epithelial cells however corroborates our results, as no 
toxicity or pro-inflammatory reactions after treatment with TiO2 NPs were observed [60].  
NM300 Ag NPs clearly demonstrated toxicity in all cell culture models used in the current 
work. LDH and Alamar Blue results showed that these particles induced a dose 
dependent toxicity in Caco-2 cell monocultures and in co-cultures in both healthy and 
inflamed conditions. However, EC50 values from LDH assays show that the Caco-2 
monoculture was more sensitive to the Ag NPs than the co-culture models (Figure 3.4). 
As a clear interaction between immune-competent cells and Caco-2 cells was observed in 
the 3D co-culture as evidenced by TEM (Figure 2.4) and CLSM (Figure 2.6) images, it is 
believed that this interaction might help to reduce the sensitivity to the toxic NPs, 
compared to the Caco-2 monocultures. It must also be mentioned however that, in spite of 
a clear toxic effect following treatment with Ag NPs, the sensitivity of the Caco-2 cell 
monocultures and 3D models to the Ag NP was overall quite low, displaying LC50 values 
more than 20-100 fold higher than for other cell lines. A research group in Scotland tested 
the same Ag NPs on C3A cells, a human hepatoblastoma cell line; cytotoxicity 
measurements showed LC50 values from 2.5 µg/cm2 (WST-1 assay; LDH assay) to 
5 µg/cm2 (Alamar Blue assay) [117], [118]. This is in contrast to the EC50 value of 
85 µg/cm2 calculated using the LDH assay for the Caco-2 cell monocultures in the current 
work, and even higher values for the co-culture models. As a point of commonality with 
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the C3A toxicity investigations however, it was observed in the current work that the 
Alamar Blue assay was not as sensitive as the LDH assay, and so a lower EC50 value 
was calculated for the particles with the LDH assay as compared to the Alamar Blue 
assay (data not shown).  
The toxic effect of Ag NPs was also observed as a disruption of barrier function, as 
indicated by recorded TEER values (Figure 3.6). TEER values decreased after incubation 
with higher Ag NP concentrations; this considerable decrease correlated well with an 
increased cell death, as inferred from a high LDH release. Furthermore, TEER profiles 
indicated that the non-inflamed triple culture was less sensitive to the Ag NPs than the 
inflamed one, in agreement with the data from LDH and Alamar Blue assays. This 
suggests that the inflamed triple culture is already in a state of stress resulting from the 
IL-1ß treatment.  
The current experiments also showed that IL-8 release was higher in the non-inflamed co-
culture than in the already inflamed one after incubation with Ag NPs. This might again be 
explained by the fact that the inflamed co-culture is already stressed by the inflammation 
and is not able to release even more IL-8. It may therefore be suggested that the non-
inflamed tissue is better protected against effects of toxic materials than the inflamed one 
as it is capable of releasing more cytokines, and perhaps is therefore better able to initiate 
activation of the immune system in order to provide protection against the toxic material. A 
high level of release of IL-8 was also observed in other studies that addressed the toxic 
potential of Ag NPs in human renal proximal tubule epithelial cells (HK-2) [118], C3A cells 
[117], and also in vivo in mice [119]. Further research groups studying cytotoxicity of Ag 
NPs in vivo found that these particles are mutagenic in mouse lymphoma cells and 
increase oxidative stress [120]. In vivo experiments of other groups showed that after oral 
uptake, Ag NPs reach the blood circulation and can be found in various other tissues not 
limited to the intestine [121]. After oral uptake it is possible that most of the NPs are 
directed to the liver because of its role in drug metabolism [122]. Therefore besides 
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experiments with intestinal models it would also be useful to test the toxicity of NPs on 
hepatocytes in vivo and in vitro. Studies have also been conducted to compare in vivo-in 
vitro correlations utilizing Ag NP toxicity data. The toxicity in human lymphocytes, plants 
and mice was tested and a very good correlation was found between the different results 
from in vitro and in vivo experiments [123]. Gaiser et al. also compared the cytotoxicity of 
Ag NPs in a hepatocyte cell line (C3A) and in mice. Similar results were found in these 
experiments with Ag NPs exhibiting cytotoxicity in the cell line and also in vivo [118].  
So far a proven explanation for Ag NPs showing such a high toxicity is not available. 
Several studies suggest that released Ag ions are responsible for cytotoxic effects [124], 
[125]. Hence in the current work, experiments were conducted with particle-free 
supernatants from Ag NPs following ultracentrifugation (Figure 3.5). No toxic effects could 
be detected, which shows that released Ag ions are in fact not the reason for the 
observed cytotoxicity, at least in the current case. This is in line with findings from C3A 
cell studies which were also not seen to be affected following treatment with particle-free 
supernatant; cells however demonstrated low viability, inflammation and oxidative stress 
upon exposure to NM300 Ag NPs [117]. Other studies with the same NM300 Ag NPs 
showed that less than 1% of the particles were dissolved in the cell culture medium used 
for experiments, which makes it very unlikely that the toxicity observed was due to the 
release of Ag ions [118].  
While it can be seen from the presented work that the current co-culture model is a very 
good setup in which to assess toxicity effects, its ability to simulate conditions in either a 
healthy or inflamed intestine also makes it a potentially very useful tool for IBD studies. A 
next step in the exploration of the possible applications of the model could therefore focus 
on efficacy rather than safety testing, and could involve observation of the deposition or 
healing effect of drug-loaded particles or other formulations. For the treatment of IBD 
patients it is important to know the deposition behavior of particles or drugs in the tissue. 
With the current co-culture model this could be determined, and a comparison made 
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between results in the healthy and inflamed state. It is also possible that the immune cells 
show an influence on the epithelial barrier properties especially during an inflammation. 
This was already shown in other studies with inflamed co-culture models for the alveolar 
region of the lung [80]. 
 
3.5 Conclusion 
The Caco-2 cell line is widely accepted as an accurate model of the normal, healthy 
intestinal mucosa, but this model cannot mimic the complex interactions between different 
cell types of the immune system and their influence on overall epithelial layer function. 
Therefore the co-culture model consisting of Caco-2 cells, THP-1 macrophages and 
MUTZ-3 dendritic cells was used to better mimic the in vivo response. 
The cytotoxicity of the various types of NPs was measured in a Caco-2 monoculture and 
in the developed co-culture model of the intestinal mucosa consisting of macrophages, 
dendritic cells and epithelial cells, in either an inflamed or non-inflamed state. The 
differences between healthy and inflamed tissue in terms of barrier permeability further 
support the importance of a model capable of mimicking diseased conditions, which 
results in different outcomes during the testing of new formulations. The presence of 
immune-competent cells as in the current co-culture model is therefore very important in 
the assessment of NP-cell interactions. Indeed, a release of pro-inflammatory cytokines 
was noted in current toxicity testing employing the co-culture, but not monoculture models, 
providing valuable information relating to inflammatory effects - an important endpoint to 
be considered in safety testing of nanomaterials. Thus, this study provides a new 3D co-
culture model of the intestinal mucosa, which can be utilized in either a healthy or 
inflamed state, suitable for assessment of toxic and inflammatory effects of engineered 
nanomaterials as well as nanoparticulate pharmaceuticals in the intestine. 
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4 Application of the cell line-based co-culture model for 
efficacy testing of anti-inflammatory formulations 
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nano- and microsized particles for inflammatory bowel disease therapy: 
evaluation of size-dependent accumulation and anti-inflammatory effect 
in an in vitro triple culture model”, to be submitted 
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the manuscript. 
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drying methods for the production of particles employed in the current 
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4.1 Introduction 
The therapy of IBD, including the chronic and severe forms of Crohn´s disease (CD) and 
ulcerative colitis (UC), is currently limited to the reduction of symptoms rather than being 
curative [126]. Therapies for IBD symptom reduction also have limits in term of their 
possible route of application; administration via pellets or tablets for example is often not 
efficient, as the frequent occurrence of diarrhea in IBD results in an enhanced elimination 
of orally-administered drug carriers and a limited drug release time [10]. Furthermore, the 
drug candidates themselves are often immunosuppressive or anti-inflammatory drugs that 
are required to be taken in daily doses, often leading to severe adverse effects [127]. Drug 
delivery systems (DDS) that carry the used drugs directly to the inflamed areas of the 
intestine would therefore be of considerable benefit for patients suffering from IBD – this 
could provide for an optimized therapy with respect to the limited drug release window, 
and, compared to a systemic application, such local treatment would allow for a dose 
reduction which could in term minimize undesired side effects.  
Depending on the severity level of CD and UC with particular respect to the degree of 
inflammation, a reorganization of the intestinal epithelium occurs and ulcerated areas also 
develop in the intestine [10], [128], [129]. It was shown that the altered intercellular 
spaces, which occur specifically in the ulcerated areas, are an accessible target for 
particulate DDS of a suitable size range. Accumulation and prolonged localization of such 
particles was seen to occur at areas of inflammation, allowing for the release of particle-
incorporated active pharmaceutical ingredient (API) specifically in ulcerated regions over 
an extended time period. Further to this study, Lamprecht et al. reported a size dependent 
accumulation of non-biodegradable polystyrene NPs in a TNBS colitis mouse model [130]. 
In contrast to this however, a recent study showed that microparticulate formulations 
seem to be favorable in terms of accumulation in ulcerated intestinal regions in human 
patients [131]. More investigations are needed to explain this apparent difference in 
optimal DDS size for accumulation in murine and human studies. Therefore, in the current 
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chapter, DDS of the biodegradable and biocompatible polymer polylactic-co-glycolic acid 
(PLGA) in both nano- and microparticle-size were developed. Two processes were 
chosen for this purpose: a nanoprecipitation method in order to produce nanoparticles of 
150 ± 10 nm, and a nano spray drying technique to fabricate microparticles (MPs) of 
~ 4 µm in a single step. Both methods were recently established at the Helmholtz Institute 
for Pharmaceutical Research Saarland (HIPS) and can be scaled-up in one set-up with 
regards to a development production scale [135].  
PLGA is a co-polymer approved by the Food and Drug Administration (FDA) for use in a 
number of in vivo devices and applications, such as in implants and as the major 
component of surgical sutures. Through hydrolysis of the ester bonds PLGA is degraded 
in the human body to its two non-toxic components, lactic acid and glycolic acid, which 
can then be further metabolized in the citric acid cycle [132], [133]. In a 50/50 (wt/wt) ratio 
of lactic acid to glycolic acid, PLGA exists in an amorphous state; this is optimal for use in 
DDS, because amorphous PLGA shows the fastest degradation rate and decomposes in 
the body within two months [95], [96]. 
As APIs for encapsulation in PLGA-based DDS the drugs budesonide (Bu) and 
cyclosporine A (CyA) were chosen. They both show anti-inflammatory effects and can be 
used for IBD therapy. Bu is generally used in a dose of 9 mg per day [136] for oral and 
rectal treatment of ileal and right colonic CD [137]. In contrast, CyA is often used in 
fulminant UC intravenously, followed by oral maintenance therapy [138], [137]. Although 
both APIs are often used for IBD treatment and show a real success in terms of alleviating 
symptoms, they also lead to several serious side effects [139]. The use of a suitable DDS 
as described above in order to reduce such side effects is therefore highly desirable. 
Several studies have already reported on loading of PLGA particles with CyA [142]–[144] 
as well as with Bu [145], [146] and some promising improvements of IBD therapy could 
already be shown as a result of the administration of these systems. Nevertheless, to our 
knowledge, a comprehensive study comparing anti-inflammatory drug-loaded nano- and 
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microparticles with regards not only to their release kinetics, but also the suitability for 
inflammation targeting and functional effects, has not yet been performed. 
To evaluate the anti-inflammatory efficacy of the developed DDS the use of an in vitro cell 
culture model was preferred, due to the numerous advantages of such models. Firstly as 
the size-dependent accumulation behavior of DDS is known to show species variability, 
an advantage of in vitro models is that human cell lines can be used to avoid this problem. 
The analysis in in vitro systems is also often easier and faster than in in vivo experiments; 
cell culture models are also less ethically questionable than animal-based testing, and, 
importantly, provide for a much easier performance of screening studies due to a reduced 
variation in readout data [51]. Furthermore, in vitro models are a first step before such 
formulations can be tested in animal models. Several cell-based in vitro models of the 
intestine [40], [41], [145] have already been developed, as shown in earlier chapters of 
this thesis. However, as also discussed, the majority of these models have a focus on 
application in transport or uptake studies. In contrast, the cell line-based three-
dimensional co-culture model developed in this thesis has the advantage over other such 
models that it does not only show good barrier properties, but can also be inflamed by 
adding IL-1ß to the apical culture compartment. Furthermore, this model contains 
macrophages and dendritic cells, which are some of the key players in inflammatory 
reactions. Important markers of inflammation such as increased IL-8 release and 
decreased TEER values can be detected and measured in this model, as demonstrated in 
previous chapters of this thesis. This triple culture model therefore has considerable 
potential as a means to accurately assess the anti-inflammatory efficacy of CyA and Bu 
PLGA particulate systems. Moreover, the model allows for physiologically-relevant 
application - DDS can be introduced to the apical compartment of the co-culture model, 
which mimics the intestinal lumen and therefore is relevant for oral/rectal application; 
likewise, addition of DDS to the basolateral compartment of the co-culture system allows 
for stimulation of treatment from the blood side (i.e. parenteral administration). The 
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relative efficacy of DDS following different routes of application can therefore be 
compared in this co-culture setup. 
In the light of the above, the aim of the study in this chapter was to test developed and 
optimized PLGA-based DDS for IBD therapy in the co-culture model of the inflamed 
intestinal mucosa. Both APIs, CyA and Bu, were encapsulated in the PLGA NPs and MPs. 
The effects of loaded PLGA NPs and MPs were then directly compared in order to 
improve the understanding of the importance of inflammation targeting and specific 
release profiles on a successful treatment of IBD. As the two drugs have different physico-
chemical properties, it was anticipated that differences in DDS encapsulation efficiencies 
and release kinetics could be seen. The known difference in pharmacological effects of 
CyA and Bu was also expected to influence the relative action of API-loaded NPs and 
MPs during DDS testing. The investigation of the size-dependent DDS accumulation at 
the site of inflammation, the anti-inflammatory effect of CyA and Bu DDS and the 
possibility to analyze these factors in vitro in the co-culture model were addressed.  
 
4.2 Materials and Methods 
4.2.1 NP preparation by nanoprecipitation 
NPs were produced by nanoprecipitation as described by Draheim et al. [135] using a 
HARVARD® Ultra PHD pump (Hugo Sachs Elektronik, Germany). PLGA (Resomer RG 
503 H; inherent viscosity 0.41 dl/g; Evonik, Darmstadt, Germany) (1.3%, w/v) and Bu 
(Caesar & Loretz GmbH, Hilden, Germany) or CyA (Fluka) were dissolved in a mixture of 
acetone/ethanol (16:3, v/v, organic phase). The solution was injected into purified water 
containing 1% poloxamer 407 (Evonik, Darmstadt, Germany) (w/v) as stabilizer. To 
determine the maximal loading capacity of NPs, increasing amounts of CyA and Bu were 
added to the organic phase during particle preparation, while keeping the amount of 
PLGA used constant. Investigated ratios of API:PLGA (wt/wt) were: 0.5:10, 1:10, 2:10, 
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3:10, 4:10 in the case of Bu, and additionally 5:10 in the case of CyA. Formed particles 
were purified and freeze dried using 0.3% (w/v) PVA and trehalose as cryoprotectant.  
For imaging the particles following application to the triple culture model, the lipophilic, far-
red fluorescent carbocyanine DiD (Invitrogen, Life Technologies GmbH, Darmstadt, 
Germany) was encapsulated in the NPs following the same protocol. A DiD stock solution 
(25 mg/ml in ethanol) was directly added at an amount of 10 µl per 10 mg of PLGA 
mixture in acetone:ethanol (16:3, v/v).  
 
4.2.2 PLGA MP preparation by nano spray drying 
A Büchi Nano Spray Dryer B-90 (Büchi Labortechnik GmbH, Essen, Germany) was used 
for the nano spray drying technique as described by Draheim et al. [135]. For the feeding 
solution 1.1% PLGA (w/v), sorbitan monostearate (Span 60, 1.6% w/v) as stabilizer and 
APIs were dissolved in acetone. To determine the optimal loading of MPs, increasing 
amounts of APIs were employed in the feeding solution, with the same amount of PLGA 
(110 mg, equal to 1.1% in 10 ml organic phase). Used ratios API:PLGA (w/w) were 0.5:10, 
1:10, 1:15, 2:10, 3:10 and 4:10 in the case of Bu, with an additional ratio of 5:10 
investigated in the case of CyA. The volume of acetone used for all experiments was 
10 ml. Feeding solution was sprayed using a 4 µm mesh under ice cooling of the supplied 
dispersion to prevent heating of the circulating solution.  
Particles containing DiD were prepared by directly adding DiD stock solution (25 mg/ml in 
ethanol) at an amount of 10 µl per 10 mg of PLGA to the feeding solution.  
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4.2.3 Determination of particle size and size distribution 
Nanoparticles 
Hydrodynamic diameter and PDI were measured by dynamic light scattering (Zetasizer® 
Nano ZS, Malvern Instruments, UK) in purified water at 25 °C and a fixed angle of 173° in 
the case of CyA- and Bu-containing NPs; as the fluorescence of DiD loaded particles 
interferes with the Zetasizer laser, the size distribution of these NPs was characterized by 
NP tracking analysis (NTA, NanoSight® LM10 HS system, NanoSight Limited, UK) 
following re-dispersion in purified water. Mean diameter (d 0.5) and percentile values d 0.1 
and d 0.9 were calculated for NP samples by the NanoSight® software.  
The zeta potential was measured for all NPs in purified water using a Zetasizer® Nano ZS 
(Malvern Instruments, UK) 
Microparticles 
Spray dried MPs were characterized by laser diffraction using a Mastersizer® 2000 
equipped with a Mastersizer® 2000 µP dispersion module (Malvern Instruments, 
Herrenberg, Germany). Particles were re-dispersed in purified water containing 
0.01% PVA under manual shaking for 10 s prior to measurement. Volume mean diameter 
(d 0.5), percentile values d 0.1 and d 0.9 and SD were calculated by the Mastersizer® 
software. Size distribution (width) is defined in Eq. 1. 
 𝑤𝑖𝑑𝑡ℎ =
𝑑 0.9−𝑑 0.1
𝑑 0.5
                       (1) 
 
4.2.4 Determination of encapsulation efficiency and optimal loading 
HPLC quantification with a Dionex system (Thermo Fisher GmbH, Idstein, Germany) was 
used for the quantification of both APIs. The system ran on Chromeleon software version 
6.80 SP2. A reversed phase column, LiChrosphere® RP18 column 
(5 µm x 125 mm x 4 mm; Merck KGaA, Germany), and an isocratic elution were used. All 
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standards were dissolved in a mixture of acetonitrile/phosphate buffer pH 3.0 (1:1, v/v). In 
case of Bu the mobile phase consisted of a mixture of acetonitrile/phosphate buffer pH 3.0 
(2:3, v/v). Oven temperature was set to 30 °C. The retention time was 4.0 ± 0.1 min 
detecting Bu with UV at 242 nm. The method was linear (r2 > 0.999) between 
2.0 µg/ml - 100.0 µg/ml with a lower limit of quantification (LOQ) of 2.0 µg/ml.  
In case of CyA, a mixture of phosphate buffer pH 3.0/methanol (1:9, v/v) was used as 
mobile phase. The retention time was 2.1 ± 0.1 min detecting CyA with UV at 205 nm. The 
method was linear (r2 > 0.999) between 10.0 µg/ml - 100.0 µg/ml with a LOQ of 6.0 µg/ml.  
To determine the amount of encapsulated API, the encapsulation efficiency (EE), an 
aliquot of API loaded NPs or MPs was dissolved in a mixture of acetonitrile/phosphate 
buffer pH 3.0 (1:1, v/v) and treated in an ultrasonic bath to disintegrate the PLGA 
particles. The solution was filtered through a syringe filter with 0.45 µm pore size 
(CHROMAFIL GF/PET 45/25); the filtrate was collected and analyzed by HPLC to 
determine the API content. 
𝐸𝐸 =
𝑚 (𝐴𝑃𝐼 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑)
𝑚 (𝐴𝑃𝐼𝑖𝑛𝑖𝑡𝑖𝑎𝑙)
∗ 100        (2) 
The EE describes the percentage of encapsulated API referring to the initial mass of API 
(Eq. 2): m (APIinitial) refers to the weight of API put into the formulation and 
m (APIencapsulated) refers to the API measured after the particle dissolution. The optimal 
loading was determined by encapsulating increasing amounts of both APIs, while keeping 
the PLGA amount constant. After washing and freeze drying, the EE was determined for 
NPs and MPs. To determine the actual loading, the mass of encapsulated API was used 
as seen in Eq. 3, which describes the actual loading as ratio of weight encapsulated API 
in mg to 100 mg of PLGA as indication for carrier capacity. Eq. 4 describes the theoretical 
loading which can be calculated from the initial amount of API referring to 100 mg of 
PLGA. 
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𝑎𝑐𝑡𝑢𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑚 (𝐴𝑃𝐼𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑)
𝑚 (𝑃𝐿𝐺𝐴𝑖𝑛𝑖𝑡𝑎𝑙)
∗ 100       (3) 
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑚 (𝐴𝑃𝐼𝑖𝑛𝑖𝑡𝑎𝑙)
𝑚 (𝑃𝐿𝐺𝐴𝑖𝑛𝑖𝑡𝑎𝑙)
∗ 100       (4) 
Both actual and theoretical loading were correlated in one graph for NPs or MPs. This 
representation can be used to determine the optimal theoretical loading that is reached if 
by increasing the initial API mass the actual loading is not increasing proportionally.  
 
4.2.5 Stability of NPs and MPs in cell culture media 
2 mg of blank, CyA- and Bu-loaded NPs and MPs were redispersed in 2 ml of Caco-2 or 
THP-1 medium (described in section 2.2.1). Particles were incubated for 24 h at 37 °C, 
with constant shaking at 100 rpm. At various time points (0, 2, 4, 8 and 24 h), 100 µl of the 
Caco-2 or THP-1 medium-particle suspension was diluted with purified water to 2 ml, in 
order to avoid light scattering of medium components e.g. proteins during subsequent size 
analysis. The size and PDI of NPs or MPs was measured as described in section 4.2.3.  
 
4.2.6 In vitro drug release 
Release profiles of APIs from loaded NPs and MPs were investigated in PBS, pH 6.8 at 
RT in triplicate. To increase the solubility of CyA, 0.05% Tween 80 (w/v) was added to the 
PBS release medium. Release studies were performed under sink conditions, which are 
defined by the United States Pharmacopeia (USP) as being in place when a value no 
greater than 30% of the API saturation concentration is present in the release medium. 
Saturation concentrations were determined to be 42.3 µg/ml for CyA and 21.7 µg/ml for 
Bu; therefore the required mass of NPs or MPs were suspended in 30 ml of the release 
medium. Release experiments were performed in stock bottles closed with Parafilm®M 
(BRAND GmbH + CO KG, Germany) to avoid evaporation. The particle suspensions were 
stirred at 400 rpm at RT for the duration of the experiments. At pre-determined time points 
1.5 ml suspension was removed and centrifuged (Hettich Rotina 420 R, Hettich Holding 
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GmbH & Co. oHG, Germany) at 24400 g at 20 °C for 15 min. 1 ml of the resulting 
supernatant was removed for analysis by HPLC as described previously. A 1 ml volume of 
fresh medium was then added to the rest of the supernatant to re-disperse the pellet, 
which was before replaced in the bulk release medium. Release was cumulatively 
calculated and normalized to the determined encapsulation efficiency of PLGA particles. 
The following values were defined for classifying the release of the different formulations: 
Fast release: >80% API released after 4 h 
Intermediate release: 50-60% API released after 48 h 
Slow release: <10% API released after 4 h and <30% after 48 h. 
 
4.2.7 Cell culture 
Cells were maintained as described in section 2.2.1. The Caco-2 clone HTB37 was used 
for the following experiments. 
 
4.2.8 Triple culture of the inflamed intestinal mucosa 
The triple culture model was seeded as described in section 2.2.3. 
Briefly, the co-culture of Caco-2, THP-1 and MUTZ-3 cells was grown until the Caco-2 
cells formed a confluent monolayer and TEER values were higher than 400 Ω*cm2. On 
day 11 cells were inflamed by adding 10 ng/ml IL-1ß into the apical compartment of the 
triple culture. Following two days of incubation, IL-1ß was removed and cells were treated 
with the different particulate formulations or APIs in solution. After 4 (Bu) or 8 (CyA) h the 
formulations were removed, cells were washed with PBS and fresh cell culture medium 
was added. TEER values and IL-8 release were measured before and as well as 1, 2 and 
3 days after formulation treatment as shown in Figure 4.1.  
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Figure 4.1: Experimental setup for NP and MP efficacy studies using the triple 
culture model. 
 
4.2.9 LDH assay 
Assessment of the cytotoxicity of NPs and MPs via LDH measurement was performed as 
described in section 3.2.5. Caco-2, THP-1 and MUTZ-3 cells were incubated with different 
concentrations of blank NPs and MPs for 8 h. Afterwards supernatant was collected to 
measure LDH release. 
 
4.2.10 TEER 
TEER measurement was performed as described in section 2.2.4.  
 
4.2.11 IL-8 measurement 
IL-8 measurement via FACS was performed as described in section 2.2.5. Analysis was 
done with FCAP array v3.0 cytometric bead array analysis software (BD Biosciences, 
Heidelberg, Germany). 
 
4.2.12 Immunostaining of the triple culture for CLSM 
Immunostaining was performed as described in section 2.2.7. As secondary antibody 
Alexa 488 anti-mouse antibody was used, diluted 1:400 in PBS. 
Chapter 4: Efficacy testing of anti-inflammatory formulations 
 
85 
 
4.2.13 Statistical analysis 
Where appropriate, data are presented as mean + standard deviation (SD). One way 
ANOVA with Holm Sidak test was used to compare results from different treatments at 
different time points. The ANOVA analysis was done with SigmaPlot 12.5 (Systat 
Software GmbH, Erkrath, Germany). Significance was assumed at p < 0.05 (*) or 
p < 0.001 (**). Individual experiments were performed in triplicate and each experiment 
was performed twice.  
 
4.3 Results 
4.3.1 Encapsulation efficiency and optimal loading 
Particulate DDS should be loaded with the highest possible API content as the DDS itself 
should only act as a transporter or reservoir for the respective API. In general the loading 
of API into DDS is a function of lipophilicity of the API, and the polymer used to prepare 
the DDS [144]. As the PLGA-based DDS were established before [135], their ability to 
encapsulate the two APIs was now tested. The optimal loading was determined; the 
values are presented in Figure 4.2A for CyA and in Figure 4.2B for Bu; the line of identity 
shows an EE of 100% which means that the actual loading would be equal to the 
theoretical loading. 
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Figure 4.2: Actual and theoretical loading of CyA-loaded (A) and Bu-loaded (B) NPs 
and MPs (mean ± SD, n≥3).                               
 
Table 4.1: Encapsulation efficiency of CyA-loaded NPs and MPs (mean ± SD, n > 3). 
Ratio Formulation 
NP [%] MP [%] 
0.5/10 53.3 ± 3.8 87.9 ± 3.3 
1/10 11.6 ± 3.6 92.0 ± 0.8 
2/10 11.0 ± 0.6 90.9 ± 3.2 
3/10 46.2 ± 9.2 90.1 ± 1.5 
4/10 67.2 ± 7.5 89.2 ± 3.8 
5/10 65.4 ± 8.7 89.0 ± 0.8 
 
 
Table 4.2: Encapsulation efficiency of Bu-loaded NPs and MPs (mean ± SD, n > 3). 
Ratio Formulation 
NP [%] MP [%] 
0.5/10 26.5 ± 2.5 91.6 ± 0.2 
1/10 36.5 ± 4.3 91.4 ± 6.3 
2/10 29.7 ± 9.9 98.3 ± 5.4 
3/10 39.1 ± 10.3 92.9 ± 6.6 
4/10 34.1 ± 7.6 94.8 ± 2.6 
 
 
For encapsulated CyA in NPs EEs between 11% and 67% were determined (Table 4.1). 
An optimal loading was fixed at a ratio of 4:10 (CyA:PLGA, w/w), which means an actual 
loading of 26.8 mg CyA/100 mg PLGA and an EE of 67.2 ± 7.5%. Nearly 100% of the 
encapsulated CyA was detected for all ratios in the MPs (Table 4.1). The optimal loading 
 NPs 
      MPs 
 line of identity 
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was fixed at the ratio 4:10 keeping the same ratio for NPs and MPs. For the CyA-loaded 
MPs the optimal loading results in 35.7 mg CyA/ 100 mg PLGA and an EE of 
89.2% ± 3.8%. 
In the case of Bu encapsulation in NPs, EE values < 40% (Table 4.2) were determined for 
all tested ratios. The optimal loading was fixed at 1:10 resulting in 3.7 mg Bu/100 mg 
PLGA with an EE of 36.5% ± 4.3% as in higher ratios the variations between different 
batches were very high. For Bu-loaded MPs SEM images show aggregates at ratios 
> 2:10 (data not shown) and the optimal loading was fixed at 2:10 resulting in 19.3 mg 
Bu/100 mg PLGA with an EE of 98.3% ± 5.4%. 
 
4.3.2 Size and size distribution of NPs and MPs 
The size and size distribution of CyA- and Bu-loaded NPs and MPs is summarized in 
Figure 4.3 and compared to unloaded particles. With respect to NPs, a slight increase in 
PDI following loading was only observed for CyA-loaded NPs (Figure 4.3A). Nevertheless 
all loaded particles had a size of 150 ± 10 nm with a narrow size distribution 
(PDI < 0.150). DiD-loaded NPs also showed a size of 144.7 ± 7.8 nm, but with a higher 
PDI of 0.81 ± 0.14. The size for blank and loaded NPs increases after freeze drying due to 
the cryoprotective agent PVA. A negative zeta potential was also determined for all PLGA 
NPs, as was expected: -27.8 ± 0.61 mV for blank, -18.9 ± 0.51 mV for CyA loaded 
and -25.0 ± 3.91 mV for Bu-loaded NPs.  
The size of all MP formulations was in the low micron size range (Figure 4.3B). Bu-loaded 
MPs showed a slight increase in size compared to blank and CyA-loaded ones, although 
these differences are not significant. No appreciable difference in size distribution was 
determined. DiD-loaded MPs showed a size of 3.95 ± 0.13 µm and a width of 2.78 ± 0.10. 
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Figure 4.3: Size and size distribution of NPs (A) and MPs (B). Blank and API-loaded 
NPs were measured by dynamic light scattering and blank and loaded MPs were 
measured by laser light diffraction (mean ± SD; n=3). 
 
Batches of both NPs and MPs were visualized by SEM (Figure 4.4) using the optimal 
loaded particles (section 4.2.4). The images confirm the small size and narrow size 
distribution of the NPs as seen in dynamic light scattering results, and show that all 
particles are smooth and spherical in shape. The surface of the MPs however appears 
rougher possibly caused by Span 60 in the composition. 
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Figure 4.4: Representative SEM images of blank, CyA- and Bu-loaded NPs and MPs, 
dispersed in water. 
A blank NPs B blank MPs 
 
 
 
 
C CyA loaded NPs D CyA loaded MPs 
 
 
 
 
E Bu loaded NPs F Bu loaded MPs 
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4.3.3 Stability of NPs and MPs in cell culture media 
Unloaded, Bu-loaded and CyA-loaded particles were incubated in the cell culture media 
used in the co-culture setup (Caco-2 and THP-1 medium) for periods up to 24 h, in order 
to test their physical stability under such conditions. Physical stability was assessed 
according to size and size distribution. Results are summarized in Figure 4.5 (NPs) and 
Figure 4.6 (MPs).  
A 
blank NP BU-NP CYA-NP
m
e
a
n
 s
iz
e
 [
n
m
]
0
20
40
60
80
100
120
140
160
180
0 h 
4 h 
8 h 
24 h 
 
B 
blank NP BU-NP CYA-NP
s
iz
e
 d
is
tr
ib
u
ti
o
n
 (
P
D
I)
0.0
0.2
0.4
0.6
0.8
1.0
0 h 
4 h 
8 h 
24 h 
 
C 
blank NP BU-NP CYA-NP
m
e
a
n
 s
iz
e
 [
n
m
]
0
20
40
60
80
100
120
140
160
180
0 h 
4 h 
8 h 
24 h 
 
D 
blank NP BU-NP CYA-NP
s
iz
e
 d
is
tr
ib
u
ti
o
n
 (
P
D
I)
 
0.0
0.2
0.4
0.6
0.8
1.0
 0 h 
 4 h 
 8 h 
24 h 
 
Figure 4.5: Stability study of NPs in cell culture media over 24 h. Size and size 
distribution of NPs incubated in Caco-2 medium (A,B) and in THP-1 medium (C,D) at 
37 °C for 4, 8, and 24 h are shown, relative to NPs freshly dispersed in medium 
(mean ± SD; n=3). 
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Figure 4.6: Stability study of MPs in cell culture media over 24 h. Size and size 
distribution of MPs incubated in Caco-2 medium (A,B) and in THP-1 medium (C,D) at 
37 °C for 4, 8 and 24 h are shown, relative to MPs freshly dispersed in medium 
(mean ± SD; n=3). 
All NPs were seen to be stable over 24 h, with no significant changes in size or size 
distribution observed following incubation in either type of cell culture medium. In the case 
of MPs, no aggregates of MPs were formed in Caco-2 medium. However, in THP-1 
medium size and size distribution increased after 24 h of incubation for all MPs. In the first 
four hours the size of the MPs decreased due to the Span 60 in the composition which is 
dispersible in aqueous phases [146]. 
Incubation times for cell culture experiments are set to 4 h for Bu- and 8 h for CyA-loaded 
particles. These time points were chosen due to the physiological relevance and the 
different modes of action of the two APIs. Thus all formulations are stable enough to be 
tested in the co-culture model. 
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4.3.4 In vitro drug release studies 
Drug release from the prepared NPs and MPs was investigated for both APIs. 
Interestingly, CyA-loaded NPs and MPs showed a different release behavior to Bu-loaded 
NPs and MPs. CyA-loaded NPs showed a low burst release after 1 h with 14.03 ± 2.4% 
followed by a very slow sustained release, typical of PLGA particles [134]. For CyA-loaded 
MPs a reduced burst release was shown with 15.9 ± 4.3% being released after 1 h 
followed by a sustained release. After 24 h nearly 100% of the initially entrapped CyA was 
shown to be released from the MPs (Figure 4.7A).  
In case of Bu, the NPs release 80% of the API in 30 min and, therefore, show a strong 
burst release. Although the particles were washed, Bu could be attached to the surface of 
the particles or located at the outer edge of the polymeric particles. Contrary to this, the 
MPs show an intermediate release with a slow and sustained release after 10 h releasing 
48% of the encapsulated Bu in 1 h. The release is promising for the investigated approach 
although 40% retain in the MPs after 24 h (Figure 4.7B). 
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Figure 4.7: Cumulative in vitro release profiles of CyA-loaded MPs and NPs (A) in 
comparison to Bu-loaded MPs and NPs (B). Release was monitored in PBS for 48 h 
(mean ± SD, n = 3).  
 
4.3.5 NP and MP cytotoxicity measurements  
Before treatment of the inflamed triple culture with the drug loaded NPs and MPs, a 
cytotoxicity assay was performed to evaluate acceptable particle concentration ranges for 
the different cell types. All cell types used in the triple culture model (Caco-2, THP-1, 
MUTZ-3) were seeded separately and incubated for 8 h with different concentrations of 
blank NPs and MPs to reflect the difference in particle concentration with corresponding 
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drug dose (Figure 4.8). MPs did not show any toxic effects on the three cell types in the 
tested concentrations (Figure 4.8B). In contrast, NPs showed 40% toxicity for THP-1 and 
MUTZ-3 cells at a concentration of 6 mg/ml (Figure 4.8A). The acceptable concentration 
range for all experiments was therefore set for Bu- and CyA-loaded NPs as 
0.006 - 2 mg/ml, and for MPs as 0.0014 - 1.4 mg/ml. 
A 
 
B 
 
 
Figure 4.8: Cytotoxicity assessment of NPs (A) and MPs (B). Particles were incubated 
with Caco-2, THP-1 and MUTZ-3 cells in monoculture for 8 h, followed by measurement of 
LDH release (mean ± SD, n = 3). 
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4.3.6 Dose finding experiments with Bu and CyA 
Prior to further cell experiments, the optimal Bu- and CyA-concentrations, which showed a 
meaningful anti-inflammatory effect on the inflamed triple culture model, needed to be 
established. Therefore, experiments with different concentrations of free CyA and Bu in 
solution were performed on the inflamed triple culture model, as shown in Figure 4.1, to 
find the lowest effective anti-inflammatory dose. 
All CyA-concentrations showed an anti-inflammatory effect, but no statistical difference 
between the effects of the different tested concentrations could be observed (Figure 4.9B). 
After 48 h the release of IL-8 was seen to increase again, because CyA is just effective 
over a short time period. The rebound increase in IL-8 release was seen to be higher in 
the co-culture treated with the lowest CyA-concentration of 0.12026 µg/ml; for the other 
two concentrations tested, the results were comparable. Therefore it was decided to use a 
concentration of 1.2026 µg/ml CyA for all further experiments. With this concentration the 
anti-inflammatory effect was seen to be acceptable; this dose also correlated to a particle 
concentration of 0.014 mg/ml for NPs and 0.008 mg/ml for MPs, which was seen from 
Figure 4.8 to be low enough to show no toxic effect. 
For Bu, all tested concentrations showed similar results: IL-8 release decreased after the 
treatment (Figure 4.9A). For this API it was therefore decided to take the lowest tested 
concentration of 0.4 µg Bu/ml which corresponds to 0.024 mg NP/ml and 
0.0056 mg MP/ml, for all further experiments. 
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Figure 4.9: Dose finding studies: IL-8 release from the triple culture model after 
treatment with free Bu (A) and CyA (B). The inflamed triple culture was treated with 
various concentrations of Bu for 4 h and CyA for 8 h. IL-8 production was then measured 
for a total of 72 h following removal of APIs (mean ± SD, n = 3). 
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4.3.7 Efficacy studies with Bu-loaded NPs and MPs 
The impact of Bu-loaded NPs and MPs was tested following application to either the 
apical or basolateral compartment of the triple culture model, simulating oral or 
intravenous administration respectively. Experiments were performed as can be seen in 
Figure 4.1. As controls non-inflamed and inflamed triple cultures that were not treated with 
any particles were used. Furthermore, for comparison free Bu solution with the same 
concentration that was contained in the particles (0.4 µg/ml), was tested, as were blank 
NPs and MPs. Figure 4.10 shows the results of TEER measurement following apical and 
basolateral treatment with Bu formulations. 
After both apical and basolateral treatment of inflamed co-cultures with Bu in solution and 
Bu-loaded NP and MP formulations, TEER values were seen to increase back to the initial 
values observed before the induction of inflammation. This phenomenon indicates a 
closing of the tight junctions between Caco-2 cells, which were opened because of the 
inflammation. In comparison, the inflamed non-treated control also showed an increase in 
TEER following removal of IL-1ß, however this occurred more slowly than in the treated 
cultures. It takes more than three days until TEER values are fully recovered when they 
are not treated with anti-inflammatory compounds. TEER values were also seen to 
increase faster after treatment with the blank formulations as in the inflamed untreated 
culture. No difference could be observed between anti-inflammatory effects of Bu-loaded 
particles and free Bu solution.  
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Figure 4.10: TEER measurement after Bu treatment of the triple culture in the apical 
(A-C) and basolateral (D-F) compartment. A,D) untreated inflamed and uninflamed 
triple cultures; B,E) treatment with Bu-loaded and blank NPs; C,F) treatment with Bu-
loaded and blank MPs. As a control result a TEER profile from inflamed triple cultures 
treated with free Bu solution is added in every graph. Bu concentration = 0.4 µg/ml for 
solution as well as loaded NP and MP samples. TEER values are expressed as a 
percentage of values recorded on day 11, prior to inflammation (mean ± SD, n = 6 from 
2 independent experiments). 
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Figure 4.11 shows the results of IL-8 release measurements following Bu treatment of the 
inflamed triple culture. IL-8 release was seen to decrease after the inflamed co-cultures 
were treated with the drug-loaded NPs and MPs. As already observed from TEER 
measurements in Figure 4.10, blank particles also showed an effect on the triple culture 
model, with cells releasing less IL-8 after treatment with unloaded particles. In the case of 
both drug-loaded and unloaded particle treatment, the decrease in IL-8 release was 
observed to occur faster in the non-treated inflamed control, confirming an additional anti-
inflammatory effect. The greatest anti-inflammatory effect was observed 24 h following 
treatment in the apical compartment, where significant differences were seen in the IL-8 
production of co-cultures treated with blank and drug-loaded particles. No significant 
difference could be observed in IL-8 production after treatment with Bu-loaded particles or 
with free Bu solution. 
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Figure 4.11: IL-8 release after apical (A) or basolateral (B) treatment of the inflamed 
triple culture with different blank and Bu-loaded NPs and MPs. Bu concentration = 
0.4 µg/ml for solution as well as loaded NP and MP samples (mean ± SD, n = 6 from 
2 independent experiments, * = p<0.05, ** = p<0.001).  
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4.3.8 Efficacy studies with CyA-loaded NPs and MPs 
Due to the different pharmacological mechanism of CyA in comparison to Bu, cells were 
incubated with the CyA-loaded particles for the longer time period of 8 h. Figure 4.12 
shows the results of TEER measurement following apical or basolateral treatment with 
CyA formulations. 
TEER value profiles in response to CyA treatment were seen to show a similar effect to 
that observed in the Bu particle study: free CyA and CyA in both NPs and MPs induced an 
increase in TEER values, corresponding to a recovery of barrier properties within the triple 
culture model. A blank carrier effect was also found here; the TEER values recovered 
faster after treatment with the blank particles as in case of the inflamed untreated control. 
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Figure 4.12: TEER measurement after CyA treatment of the triple culture model in 
the apical (A-C) and basolateral (D-F) compartment. A,D) untreated inflamed and 
uninflamed triple cultures; B,E) treatment with CyA-loaded and blank NPs; C,F) treatment 
CyA-loaded and blank MPs. As a control result, a TEER profile from inflamed triple 
cultures treated with free CyA solution is added in every graph. CyA 
concentration = 1.2026 µg/ml for solution and loaded NP and MP samples. TEER values 
are expressed as a percentage of values recorded on day 11, prior to inflammation 
(mean ± SD, n = 6 from 2 independent experiments). 
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Figure 4.13: IL-8 release after apical (A) or basolateral (B) treatment of the triple 
culture with different blank and CyA-loaded NPs and MPs. 
CyA concentration = 1.2026 µg/ml for solution and loaded NP and MP samples 
(mean ± SD, n = 6 from 2 independent experiments). 
 
Investigation of IL-8 secretion following CyA treatment (Figure 4.13) showed a 
comparable effect to that observed with Bu treatment. IL-8 release was seen to decrease 
after treatment with the different CyA formulations; additionally the effect after treatment in 
the apical compartment was higher than after treatment in the basolateral compartment. 
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As in the experiments with Bu, an anti-inflammatory effect of the blank formulations was 
also observed. However, a significant difference in IL-8 production 24 h after apical 
treatment with blank as compared to CyA-loaded formulations was determined as it was 
the same case after treatment with Bu-loaded formulations. Furthermore, after 24 h a 
significantly higher anti-inflammatory effect of the CyA-loaded NPs in comparison to the 
free drug solution could be observed. 
 
4.3.9 Deposition of NPs and MPs in the triple culture model 
The inflamed triple culture model was incubated with NPs and MPs loaded with the far-red 
fluorescent dye DiD, applied to either the apical (Figure 4.14) or the basolateral 
(Figure 4.15) compartment. The particle concentrations and incubation times were 
equivalent to those used in the efficacy studies: 0.024 mg/ml NPs and 0.0056 mg/ml MPs 
with 4 h of incubation in the case of Bu, and 0.014 mg/ml NPs and 0.008 mg/ml MPs with 
8 h of incubation for CyA particles.  
Confocal images (Figure 4.14) show that NPs as well as MPs were located on top of the 
Caco-2 cells of the cell culture model when they were incubated in the apical 
compartment, despite the fact that the cells were washed several times after incubation 
with the particles. MPs may stick on top of the cells due to their bigger size and as such 
were seen distributed over the cell borders (Figure 4.14A/C). NPs were in fact taken up by 
Caco-2 cells. Figure 4.14 B and D show that the NPs were located inside the cells, rather 
than being located on the cell borders. After basolateral treatment no particles could be 
found in the co-culture model (Figure 4.15). 
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Figure 4.14: CLSM pictures of the inflamed triple culture incubated with DiD-loaded 
NPs and MPs in the apical compartment. A) DiD MPs CyA concentration; B) DiD NPs 
CyA concentration; C) DiD MPs Bu concentration; D) DiD NPs Bu concentration; 
scale bar = 50 µm; blue: DAPI stained nuclei, green: tight junctions stained with anti-
occludin antibody, red: DiD loaded particles 
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Figure 4.15: CLSM pictures of the inflamed triple culture incubated with DiD-loaded 
NPs and MPs in the basolateral compartment A: DiD MPs CyA concentration; B: DiD 
NPs CyA concentration; C: DiD MPs Bu concentration; D: DiD NPs Bu concentration; 
scale bar = 50 µm; blue: DAPI stained nuclei, green: tight junctions stained with anti-
occludin antibody, red: DiD loaded particles 
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4.4 Discussion 
DDS can improve the therapy options for IBD patients as they can passively accumulate 
in inflamed areas of the intestine [130]. By forming a depot at the site of inflammation 
where treatment is needed, the incidence of systemic adverse effects can be reduced. 
Studies showed that NPs seem to be favorable for accumulation in inflamed areas in 
mouse models [130], [147], whereas MPs show a better deposition efficacy in human 
patients [131]. Such studies showed an enhanced accumulation of MPs in the ulcerated 
lesions, whereas NPs were only found in traces in the mucosa of patients with CD and 
UC [131].  
Nanoprecipitation is one of the most frequently used methods for the preparation of 
polymer-based DDS [149], [150], [151]. In comparison to emulsion-diffusion-evaporation 
methods it shows reduced production times, increased reproducibility and controllability 
and less production steps [151]. The produced NPs were in suspension and had to be 
converted into a more stable, storable form by freeze drying. For this process, a suitable 
cryoprotectant with regards to the prevention of particle aggregation and to the 
achievement of a maximum stabilization of NPs during freeze drying must be evaluated. 
In the current work, trehalose was revealed to be the optimal cryoprotectant when used in 
combination with PVA, which can attach to PLGA NP surfaces [155]. This can result in a 
slight increase in particle size after freeze drying, as was noted in Figure 4.3. Furthermore 
we propose that free PVA that is not attached to the surface of the NPs can act as a 
stabilizer. PVA prevents aggregation during freeze drying as it forms a glassy state at low 
temperatures [155]. Moreover it forms hydrogen bonds between the polymer and water 
molecules, contributing to a better particle redispersion [156].  
The spray drying technique was used to formulate DDS in a single step process, without 
the need for extra washing or drying steps [157]. The used novel nano spray drying 
system was especially developed to produce spray dried products in the sub- or low-
micron size range, achieved by a vibrating mesh which transports the feeding solution into 
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the drying gas flow [158]. Studies performed with this relatively new system have 
investigated the spray drying of nano-emulsions [157] and of pharmaceutical excipients 
and proteins [159]. Further studies have focused on the preparation of particles using 
polymeric wall material and proteins [160] [161] and encapsulation of model drugs in 
biodegradable polymers [159], [163].  
In this study the APIs Bu and CyA were encapsulated in MPs and NPs for the treatment of 
IBD. The calcineurin inhibitor CyA is commonly administered to UC patients suffering from 
fulminant colitis that does not respond to intravenous corticosteroids [163]. The therapy is 
started intravenously for three to five days, and is then typically continued in oral form 
often in co-medication with corticosteroids and thiopurines for maintenance therapy [137]. 
CyA therapy is associated with adverse effects for example neurological toxicity, 
infections, renal dysfunction and hypertension [137]. Bu, a corticosteroid, is a first-line 
agent for ileal and/or right colonic CD [136], [127]. It is utilized both as oral and local 
formulation (as foam or enema) [137]. Bu has an extensive first-pass metabolism, 
reducing the systemic bioavailability to 10 – 15% after oral administration [144], which 
maximizes its locally available concentration in the distal ileum and proximal colon [128].  
In vitro release studies are a useful research tool to estimate release kinetics and show 
comparisons between various DDS samples and batches. PLGA-based DDS show in 
general a biphasic release profile, starting with a burst release followed by a sustained 
one [134]. Release of APIs from DDS is driven by three basic mechanisms: 
a) swelling/erosion, b) diffusion and c) degradation [164]. The produced DDS in this study 
show an improvement in the release compared to recent studies of CyA-loaded PLGA 
MPs [143], [166], which revealed a sustained and incomplete drug release over a number 
of weeks, up to a maximal value of 60% after 50 days [142]. Also for CyA loaded NPs a 
drug release over three weeks or more was reported, with the use of PLGA 50:50 
(lactide:glycolide ratios) showing in general the faster release rates [143], [166]. The in 
vitro release profiles of Bu-loaded DDS in the current work revealed a dramatic burst of 
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80% for NPs in comparison to 40% for MPs. This shows that Bu is probably more 
adsorbed at the surface or encapsulated at the outer edge of the particles. It is interesting 
that the release profiles are so different for NPs as compared to MPs. MPs release might 
be supported by the stabilizer, which is dispersible in aqueous solutions [146], and by the 
crystallization processes during MP formation. The spray drying process may produce 
micro voids in the MPs, supporting water penetration [166], which could explain the faster 
release of CyA from MPs in comparison to NPs. 
A fast release from MPs as seen in the case of CyA could be a benefit for administration 
as they are supposed to be cleared faster, because the accumulation of particles is size-
dependent and NPs are supposed to accumulate at a higher content, building a depot in 
the inflamed regions [29]. Moreover DDS will not stay in the inflamed areas for an endless 
time due to for example the regeneration of the epithelium. Lamprecht et al. determined 
an accumulation of 100 nm polystyrene NPs at 9.1 ± 2.8% after four days, which 
decreased after six and eight days to 3.4 ± 2.2% and 1.9 ± 1.1%, respectively [130].  
The most important point for this study was the investigation of whether the produced 
particles showed the desired anti-inflammatory effect. Therefore the formulations loaded 
with CyA and Bu were tested in the cell line-based co-culture model of the inflamed 
intestinal mucosa by measurement of TEER values and IL-8 release, and it was seen to 
be persistent enough to allow for the functional evaluation of the anti-inflammatory 
formulations.  
As expected, DDS containing both CyA and Bu showed anti-inflammatory effects in the 
triple culture model. After treating the inflamed cells with the drug-loaded NPs and MPs in 
the apical compartment, TEER values increased again in comparison to values seen 
before inflammation. The self-healing process of the triple culture also leads to a recovery 
of TEER, which was monitored in the non-treated inflamed control; however this self-
healing was seen to take more time than when cells were treated with the formulations. 
TEER values indicated a strong anti-inflammatory effect of the produced formulations; 
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however this effect was not precise enough to detect any differences between CyA-loaded 
particles, Bu-loaded particles or blank NPs and MPs. The pro-inflammatory marker IL-8 
was therefore also measured as this is expressed in high amounts in the intestine of IBD 
patients [113]. IL-8 production proved to be a very important marker for our experiments, 
with release from the inflamed triple culture models seen to decrease already 24 h after 
treatment with the different formulations. A rebound release was seen following this initial 
increase however, because both drugs show an effect just over a short time period.  
Results after treatment with Bu NPs and MPs were similar to results following treatment 
with Bu as free drug. In case of the NPs this is very much expected in consideration of the 
release profile, which shows that the drug is released very fast from the formulation 
(Figure 4.7B). In the case of the MPs however, the release profile (Figure 4.7B) shows 
that after 24 h only approximately 60% of Bu is released and available in free form, which 
means that the effect of the Bu-loaded MPs could be seen as being better than the effect 
of the Bu solution, because less API is available. This could be explained by MP 
accumulation in the model (Figure 4.14), meaning that the encapsulated API is not 
washed away and can be released over the whole experimental time.  
In the case of CyA a significant difference between the effect in terms of IL-8 production of 
CyA NPs and free drug solution was observed. The release profile (Figure 4.7A) shows 
that CyA is released more slowly than Bu from the NPs, which means that the released 
drug can reach the cells over a longer time period. Due to their small size, NPs can be 
taken up by Caco-2 cells, which could be observed in chapter 2 of this thesis (Figure 3.8). 
TEM pictures have shown that Caco-2 cells can take up 15 nm Au NPs in vesicles [103]. 
Although the difference in IL-8 production observed between free drug and drug-loaded 
MPs was not significant, there is a similar trend as compared to the results from the NPs. 
Figure 4.14 shows that NPs were found inside the cells, whereas MPs were deposited on 
top of the cells and are distributed over the cell borders. MPs (~4 µm) are probably too big 
to be taken up by the Caco-2 cells; however, they still appear to stick on top of the Caco-2 
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cells, and so remain at the site of action releasing drug. Furthermore, as indicated from 
the low TEER values, the tight junctions of the inflamed triple culture are likely to be open 
(due to lower expression of tight junction proteins ZO-1 and occludin) [76]; the pores 
created by open tight junctions have been reported to have a size of 58 – 104 nm [167] 
meaning that, while the MPs are unlikely to be able to pass through they may become 
trapped and accumulate in these enlarged intercellular spaces. This phenomenon has 
also been reported by Leonard et al. [68]. 
Blank formulations also showed an anti-inflammatory effect, which has already been 
observed in other studies [51], [89]. One reason for this could be the adsorption of soluble 
signaling parameters involved in the inflammatory cascade of IL-8, to particle surfaces. 
Another possibility is that blank particles interact with the immune cells within the triple 
culture, and lead to a response of the immune system with this new stimulus [68]. Further 
studies have to be performed to show why this effect occurs. However in vivo studies 
have also shown that the released lactate from PLGA leads to wound healing in mice 
[169], [170], which also shows that PLGA can have a healing and pharmacological effect. 
The particles were not only tested in the apical compartment, but also in the basolateral 
one, which mimics the blood side in the model. Although no significant differences 
between blank and Bu- and CyA-loaded particles were observed after treatment in the 
basolateral compartment, the results show the same trend as after apical treatment: drug-
loaded particles led to a better effect than blank ones. Confocal images showed that NPs 
and MPs could however not reach the cells when they were added basolaterally 
(Figure 4.15). MPs are expected to sediment directly to the bottom of the plate, meaning 
that their lack of interaction with the cells is not surprising, but NPs also could not reach 
the apical compartment – this could be due to the barrier of the filter membrane and the 
collagen layer. Furthermore they were removed by changing the medium during the 
experiment, which shows that only the released drug was capable of reaching the 
inflamed cells.  
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In this study it was shown that the anti-inflammatory effect of drugs can be tested on the 
developed triple culture model consisting of three cell lines. However, the system also 
shows certain limitations – while it could be determined whether a tested compound 
demonstrated an anti-inflammatory effect or not, relative differences in anti-inflammatory 
function were difficult to distinguish. A further limitation is testing of DDS in the basolateral 
compartment, which mimics administration via the blood side. It was observed here that 
DDS cannot reach the cells, either because of sedimentation or due to the barrier action 
of the transwell filter and collagen layer. Both factors are of course unlikely to occur in the 
in vivo situation. A further deviation from the in vivo situation in the current model is the 
lack of flow behavior. In order to attempt to mimic the flow through the intestine the cells 
were washed to be sure any non-adherent DDS were removed; however, the model would 
be even more realistic if there would be a fluid rather than a static system. Nevertheless, 
in vitro testing in this model is closer to the in vivo situation than testing with cell 
monocultures, and the ability to simulate and monitor inflammation in the model through 
IL-8 measurement offers a comparison to IL-8 production in in vivo experiments. Oral 
DDS could also be tested in the apical compartment and showed realistic results, which 
gives a promising perspective to the use of produced particles for oral IBD treatment as 
well as to the model, following further development, for in vitro testing for such 
formulations. 
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4.5 Conclusion 
Optimized PLGA-based pharmaceuticals for IBD therapy according to the demands of a 
scalable and quality controlled production and storage could be successfully loaded with 
cyclosporine A and budesonide.  
The anti-inflammatory effect of these model drugs could be successfully tested on the 
triple culture model consisting of three cell lines (epithelial cells, macrophages and 
dendritic cells) using TEER and IL-8 measurement as meaningful markers for 
inflammation. The investigation of the size-dependent accumulation at the site of 
inflammation and the anti-inflammatory efficacy was possible following application of DDS 
from the apical side. Furthermore it could be shown that the co-culture model is a useful 
tool for this testing because of the reversibility of the inflammable status. 
Therefore this model can be considered as a first step for the testing of oral anti-
inflammatory drugs before they are tested in animal models, giving a perspective for a 
reduction in the number of time-consuming and expensive animal tests. 
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Summary and outlook 
The current study has shown the successful replacement of primary immune cells by the 
cell lines THP-1 and MUTZ-3 in a 3D co-culture model of the intestinal mucosa. After 
inflammation the model showed the same behavior as the previous, primary immune cell-
based setup. The using of cell lines makes this model much easier to seed in a more rapid 
manner; it also makes the model more reproducible because primary cells were isolated 
from different persons and showed a higher variability than cell lines. 
The model has been proven in the current work to be a useful tool for safety testing of 
nanomaterials. It could be seen that toxic Ag NPs exerted different effects on the co-
culture model in comparison to a Caco-2 monoculture: Caco-2 cells alone were more 
sensitive to the toxic NPs than the co-culture systems, reinforcing the important role of 
immune cells in these measurements by virtue of their production of pro-inflammatory 
cytokines and also their apparent protection of the tissue. It was further shown that 
cytokine measurement is quite important in order to assess and monitor inflammation, as 
differences in IL-8 release from the cell cultures after treatment with NPs could be seen 
that did not correspond to any measurable toxic effects. Additionally cytokine 
measurements can also be performed in in vivo models to be compared to in vitro results. 
Furthermore the optimized model can also be used to test anti-inflammatory effects of 
newly developed nano- and microparticulate DDS. By measuring TEER and IL-8 release 
the anti-inflammatory action of such DDS can be measured within this system. 
Additionally, the deposition of particles in the model could be investigated by CLSM. 
There are still some limitations in the co-culture system which need to be assessed in 
further work however. The first point for further investigation should be the collagen layer 
underlying the Caco-2 cells in which the immune cells are embedded. It is still not clear if 
NPs are able to cross this layer and therefore if all the immune cells can get in contact 
with the particles. The collagen could also be a hindrance to the testing of anti-
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inflammatory compounds applied to the basolateral compartment, as, along with the filter 
membrane, it forms a physical barrier to compound interaction with the cells. A next step 
in the model development could therefore be to replace this collagen by another matrix. 
Furthermore, the system is not so sensitive that differences in the effect of different 
concentrations of anti-inflammatory compounds can be observed. Regarding these points, 
the model could still be improved by carrying out further studies. 
Nevertheless, though there are points for further consideration, the model has still shown 
a lot of promise for toxicological testing and also for anti-inflammatory drug efficacy 
assessment. 
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